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HISTORICAL PERSPECTIVE 
In 1832 the French philosopher and scientist Michel Eugene Chevreul 
successfully extracted creatine from meat (the muscles of mammalians) and 
named it “creatine” from the Greek word κρέας (kreas), meaning “meat”. 
After Chevreul’s discovery, Justus von Liebig, a German chemist, in 1847 
demonstrated that creatine concentration was higher in wild animals 
compared to domestic ones and he concluded that creatine concentration in 
muscular tissue was dependent upon the level of activity. 
In 1912, researchers at Harvard University showed that ingestion of 
creatine could rise muscular creatine content and later studies demonstrated 
that creatine supplementation induced nitrogen retention suggesting 
increasing protein content in muscle. This effect was reversible with the 
withdrawal of creatine (Haffernan, 2015). 
In 1923 the content of creatine in human body was measured in about 
100 grams, 95% of which stored in muscle tissue. In the light of all these 
findings, Alfred Chanutin, in 1926, for the first time studied the effect of 
creatine in humans. He administered 10 g of creatine a day for a week and 
found increased creatine content in muscles, proposing that creatine have 
anabolic effects (Chanutin, 1926). 
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In 1990s the use of creatine as anabolic agent to increase athletes’ 
performance began and currently creatine is one of the most popular 
supplements in sport (Balsom, Söderlund and Ekblom, 1994). 
In 1994, in a patient with extrapyramidal movement disorder and low 
creatinine concentration in serum and urine, by using proton magnetic 
resonance spectroscopy, a generalized depletion of creatine in the brain was 
described for the first time (Stöckler et al., 1994). When the Authors tried to 
treat the patient with arginine (a creatine precursor), they found that the 
metabolite guanidine acetate increased in the brain, not paralleled by an 
increase in creatine, indicating that the defect was in the second of the two 
enzymes responsible for creatine synthesis (see below).  
In 2001 another patient presenting with developmental delay and 
hypotonia was found to have low brain creatine content: but in this case 
serum and urine creatine levels were increased (Salomons et al., 2001). 
Genetic analysis revealed a nonsense mutation in gene coding for creatine 
transporter and low uptake of creatine in fibroblasts coming from the patient. 
This was the first description of the clinical syndrome due to genetic defects 
of the creatine transporter. 
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PHYSIOLOGY OF CREATINE AND ITS TRANSPORTER 
CREATINE BIOCHEMESTRY 
Creatine (Cr) is a nitrogenous organic acid found in vertebrates having 
many physiologic functions, some of which have only recently been being 
investigated. The best-studied role of Cr is its function as transient 
intracellular storage of high-energy phosphate bonds, used to regenerate 
adenosine triphosphate (ATP) starting from adenosine diphosphate (ADP) 
and from the phosphorylated form of Cr (phosphocreatine, PCr) in the 
following reversible enzymatic reaction (Figure 1) catalyzed by the enzyme 
Cr kinase (CK): 
 Phosphocreatine + ADP  creatine + ATP. 
 
Figure 1. The creatine cycle. 
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Consistently with this energetic role, tissues with high metabolic rates 
have a large pool of PCr in order to regenerate ATP fast during intense use.   
 The so called “creatine cycle” also acts as transport system for 
phosphate bonds between sites of production (mitochondria, glycolysis) and 
sites of consumption inside the cell. The mitochondrial form of CK 
phosphorylates Cr to PCr reducing the ATP/ADP ratio to a level that allow 
ATP synthase to continue working. On the other side of the mitochondrial 
membranes, in the cytoplasm, PCr is used at sites of high metabolic 
requirements to restore ATP starting from ADP. The Cr produced in the last 
reaction diffuses back to mitochondria completing the Cr cycle. According to 
this view, the transport of high-energy phosphates from production to 
consumption sites is ensured mainly by means of PCr-Cr cycle. Cr and PCr 
are molecules smaller and less negatively charged compared to ATP or ADP; 
these properties could allow reaching higher concentrations and then a more 
efficient flux of high-energy phosphates in cells strongly relying upon Cr 
cycle (Wyss and Kaddurah-Daouk, 2000). 
The major share of Cr (and PCr) in human body is found in muscle, up 
to 30 mM. The brain, as expected by its high metabolic rate, contains a 
concentration of Cr of about 10 mM (Wyss and Kaddurah-Daouk, 2000).  
Many other functions of Cr have been described or hypothesized. It is 
an osmolyte and has anti-oxidant and anti-apoptotic effects (Andres et al., 
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2008). The release of Cr into the synaptic cleft was observed and a putative 
role as neuromodulator or even as true neurotransmitter has been envisaged 
(Almeida et al., 2006). Cr is now widely used as nutritional supplement, and 
its use in different neurological or psychiatric disorders like mitochondrial 
encephalopathy, stroke, traumatic neurological injury, neurodegenerative and 
muscular disorders has been tested (Andres et al., 2008; Evangeliou et al., 
2009). 
CREATINE SUPPLYING 
There are two ways by which normal levels of Cr can be achieved and 
maintained in tissues in physiological conditions: (I) endogenous synthesis 
and (II) exogenous intake by food. Both contribute to the amount of this 
metabolite in normal tissues. 
The synthesis of Cr is a two-step reaction which requires the amino 
acids arginine (Arg) and glycine (Gly) as initial reagents. The enzyme L-
arginine:glycine amidinotransferase (AGAT) transfers the amidino group of 
Arg to Gly in order to produce L-ornithine and guanidinoacetic acid (GAA). 
In the second step the enzyme S-adenosyl-L-methionine:N-guanidinoacetate 
methyltransferase methylates the amidino group of GAA to produce Cr 
(Figure 2).  
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Figure 2. The synthesis of creatine. 
 
During evolution AGAT and GAMT have probably evolved with 
lamprey and they are not detected in invertebrates whereas they are present in 
most, but not all, vertebrates. Nevertheless, some invertebrates contain 
significant amount of Cr, of its phosphorylated metabolite and of CK, 
suggesting mechanisms for the uptake of Cr from environment or not yet 
detectable synthesis enzymes. Notably, from an evolutionary point of view, 
in invertebrates lacking Cr the same function of energy storage is held, in an 
analogous reaction to the Cr cycle, by Arg, that is one of the precursors of Cr. 
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Despite the seeming simplicity of the Cr cycle, the biochemical 
picture is complicated by the fact that many tissues seem to lack one of the 
enzymes involved in the synthesis of Cr or its precursors. 
Mammalian kidney expresses high levels of AGAT but usually low 
levels of GAMT. Liver, on the contrary, contains high amounts of GAMT 
and low levels of AGAT in most species. However, monkey and human also 
have high amounts of AGAT in liver, whereas common laboratory mammals 
such as rats and mice seem to be devoid of AGAT activity in this tissue 
(Wyss and Kaddurah-Daouk, 2000). This pattern of biosynthetic enzyme 
expression could relate to some differences noticeable in phenotype between 
humans and mice affected by Cr metabolism disorders. Based on these 
findings, the following outline about Cr synthesis in mammals has been 
proposed: the kidney would be the main site of GAA production; this 
metabolite is then transported through blood to liver where it is methylated to 
Cr (Figure 3). Finally, Cr is again transported by blood to all tissues where it 
is taken up.  
In contrast, other findings described a reduction of Cr synthesis in 
models with nephrectomy (Levillain, Marescau and Deyn, 1995), suggesting 
that, notwithstanding the possible expression of both enzymes in human 
liver, kidney could nevertheless be required for Cr synthesis. Therefore, the 
biochemical pathways of Cr metabolism and the exchange of Cr and its 
metabolites among many tissues or cell types seem more complex. 
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Furthermore, differences in mammal species make findings in one species 
difficult to apply to other ones, and particularly to human. 
 
Figure 3. Hypothesized model of Cr synthesis in mammals (Wyss and Kaddurah-Daouk, 2000) 
 
Finally, Cr and PCr are non-enzimatically converted into creatinine, 
which diffuses out of the cells and is excreted by the kidneys into the urine. 
By this catabolic pathway about 1.7% of the total Cr pool of the body is lost 
every day and needs to be replaced (Wyss and Kaddurah-Daouk, 2000). 
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CREATINE TRANSPORTER 
Cr can be taken up by ingested food and about one-half of the daily 
required Cr amount is provided by this way (Brosnan and Brosnan, 2007). 
For this purpose, a Cr transporter (CrT) exists that is responsible for a 
saturable Na+- and Cl--dependent uptake into cells against a large 
concentration gradient.  
The CrT is encoded by the SLC6A8 gene that in human is located on 
Xq28. It is made up of 13 exons, with a predicted protein of 635 amino acids 
and a molecular mass of 70.5 kDa (Guimbal and Kilimann, 1993). It is a 
member of the SLC6 family of Na+- and Cl-- dependent plasma membrane 
transporters for neurotransmitters which encompasses transporters for 
GABA, norepinephrine, dopamine, serotonin, glycine, taurine, proline, and 
betaine (Kristensen et al., 2011). Like the other members of the SLC6 family, 
the CrT consists of 12 transmembrane domains, containing sites for N-
glycosylation and several sites for phosphorylation. 
In humans, CrT is expressed predominantly in muscle, kidney and 
heart, and also in many other tissues including brain (Iyer et al., 1996). This 
pattern of expression reflects the high levels of Cr in muscle and heart and 
the important role of kidney in Cr reuptake from urine (Guimbal and 
Kilimann, 1993). 
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The CrT is expressed in kidney in the apical membrane (the brush 
border) whereas little or no expression is identifiable in the basolateral 
membrane (García-Delgado et al., 2001). That is, the Cr is transported from 
the tubular lumen into the cell and this mechanism requires that a different 
and still unknown Cr transporter must be expressed on the basolateral 
membrane domain in order for Cr to exit the cell into the bloodstream. A 
very similar pattern of expression is observed also in small intestine where Cr 
introduced with food is absorbed (Nash et al., 1994). 
CREATINE TRANSPORTER EXPRESSION IN BRAIN 
CrT is expressed in many structures of the brain, particularly in the 
olfactory bulb, cerebellum, hippocampus, cortex and several brainstem nuclei 
(Braissant et al., 2008). Regarding the cell types, CrT expression is found in 
both neurons and glial cells. However, the CrT presence in glial cells is still 
debated. In some studies, CrT is expressed in oligodendrocytes but not in 
astrocytes (Braissant et al., 2005), whereas other Authors found expression 
also in astrocytes (Carducci et al., 2012). The differences observed could be 
explained by differences in materials and methods used.  
According to in vitro studies of rat hippocampal neurons, CrT is 
mainly expressed in dendrites and in some axon terminals (Dodd et al., 
2010); this localization can be explained by the high energy requirements for 
re-establishing the ion electrochemical gradients disrupted during neuronal 
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signaling but also for its envisaged role as neurotransmitter. Evidence was 
found of the presence of CrT in synaptosomal membrane, which would 
precisely be the expected place where CrT should be found if Cr were 
secreted as neurotransmitter/neuromodulator (Peral, Vázquez-Carretero and 
Ilundain, 2010). 
A recent transcriptional analysis led to discovery that CrT is highly 
expressed in fast-spiking neurons parvalbumin-positive (PV+) inhibitory 
interneurons (Saunders et al., 2018). This observation well fits the hypothesis 
that higher Cr concentration can be required in fast-spiking neurons in order 
to meet the high energy needs of this cell type.  
CREATINE UPTAKE REGULATION 
The uptake of Cr is strictly regulated by many factors, first of which is 
Cr itself that decreases its own uptake (Loike et al., 1988). This control 
mechanism is important to avoid accumulation of high concentration of Cr 
and subsequent ATP depletion. 
Among the other important factors, AMP activated protein kinase 
(AMPK), which is involved in regulating energy homeostasis by 
downregulating energy consuming pathways in favor of energy generating 
processes, inhibits CrT activity and expression in the apical membrane of 
kidney proximal tubule cells, possibly indirectly via inhibition of mTOR (Li 
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et al., 2010), exemplifying the complex signaling network responsible for Cr 
regulation, aimed at matching Cr concentration to current cell energy 
requirements.  
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CREATINE TRANSPORTER DEFICIENCY 
ETIOLOGY 
Thanks to proton magnetic-resonance spectroscopy (1H-MRS) it is 
possible to measure concentration of Cr, and other metabolites, in the brain. 
This technique allowed discovering Cr deficiency conditions as definite 
disorders of Cr metabolism. Three cerebral Cr deficiency syndromes (CCDS) 
have so far been described, all of them characterized by severe intellectual 
disability.  
GAMT-deficiency was the first CCDS to be described in 1994 
(Stöckler et al., 1994), followed by the discovery of the other two conditions, 
AGAT and CrT deficiency (CTD, also named CCDS1) (Item et al., 2001; 
van de Kamp, Mancini and Salomons, 2014). The two enzymatic disorders 
(AGAT and GAMT-deficiency) impair Cr synthesis and are inherited in an 
autosomal recessive manner. The defect of the transporter impairs Cr uptake 
by the cell and it is an X-linked disease. It was estimated that CrT deficiency 
can be the etiology of about 2% of the cases of intellectual disability in males 
(van de Kamp, Mancini, and Salomons 2014).  
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CLINICAL FEATURES 
The clinical picture of patients affected by Cr deficiency syndromes is 
dominated, in all the three genetic disorders, by intellectual disability, 
seizures and autistic-like behavior. Patients with GAMT defects can also 
show aggressive and self-injurious behaviors (Mercimek-Mahmutoglu et al., 
2006). 
More specifically, CCDS1 is characterized by intellectual disability 
with sever speech delay which involves virtually the totality of patients; 
behavioral abnormalities and seizures are common. Moreover, the 
intellectual disability seems progressive (van de Kamp et al. 2013). Some 
patients have autistic-like features, others show hyperactivity. The motor 
system is less impaired: a delay in acquisition of independent walking can be 
observed, as well as subtle extrapyramidal alterations in some patients, but a 
clear muscle weakness has only rarely been described in human (van de 
Kamp et al. 2013). 
MRS reveals the most characteristic feature of CrT deficiency: the 
severe depletion of Cr in the brain. Cr content in human muscle seems 
preserved in CrT defects whereas it is reduced in defects involving the two 
biosynthetic enzymes (deGrauw et al., 2003; Edvardson et al., 2010).  
Laboratory findings help clinicians to diagnose CrT disorders. The 
defect of CrT is characterized by an increased urine Cr/creatinine ratio, 
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probably due to the impair in renal reabsorption of Cr. Cr plasma levels are 
normal while Cr in cerebro-spinal fluid (CSF) are normal or increased, 
similar to what happens in some other defects of neurotransmitter 
transporters, like serotonin transporter (van de Kamp et al. 2013). 
Moreover, some patients affected by CrT defects show biochemical 
markers peculiar to mitochondrial encephalopathies (increased plasma 
lactate, urinary 3-methylglutaconic, tricarboxylic acid cycle intermediates 
and secondary decreases of variable respiratory chain complexes) (Hathaway 
et al., 2010). These findings are not surprising if the energetic role of Cr in 
cell and mitochondrial metabolism is considered. 
GENETIC AND INHERITANCE 
Many different types of genetic mutations affecting the SLC6A8 gene 
have been described: missense and nonsense mutations, splice error 
mutations (intronic or synonymous variants with aberrant splicing), a 
translation initiation site mutation and multi-exon deletions (LOVD database 
(http://www.LOVD.nl/SLC6A8)). In some cases, a missense mutation can 
result in a residual transporter function which in turn can, in some cases, be 
associated to a mild phenotype (Betsalel et al., 2012). Most of the genetic 
alterations observed are concentrated in the transmembrane domains 7 and 8 
of the protein (van de Kamp et al. 2015). 
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Because the SLC6A8 gene is located on chromosome X, the disorder is 
an X-linked condition. About one third of the cases are due to de novo 
mutations (van de Kamp et al. 2013). The disorder mainly affects male 
patients, but female patients can show a mild symptomatic phenotype (van de 
Kamp et al. 2011). In these cases, diagnosis can be difficult because of the 
clinical pictures and a higher frequency of normal biochemical markers. 
Female phenotype variability is higher than observed in male, due to the 
random inactivation of X chromosome. 
PATHOPHYSIOLOGY 
As described, a biosynthetic pathway exists for Cr synthesis; 
nevertheless, the defect of the transporter gives rise to a severe disorder. This 
seems to suggest that the biosynthetic pathway alone is not sufficient to 
provide the necessary amount of Cr or, as discussed above, not every tissue 
may be able to carry out the whole synthetic reaction. These tissues would 
rely upon the CrT in order to exchange Cr or its metabolites. 
On the other side, the observation that some tissues seem spared in 
CrT defects, like muscle in human patients, probably means that in these 
tissues the enzymatic pathway is fully expressed and working, and it is able 
to ensure the provision of Cr content in absence of any exogenous source. It 
is probable, therefore, that in most tissues both mechanisms, uptake and 
synthesis, are active and required to maintain normal Cr concentration. 
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Notwithstanding the expression of AGAT, GAMT and CrT is 
described in neurons and glial cells, uptake of Cr in brain from blood seems 
limited (Perasso et al., 2003), as also indicated by the fact that in Cr synthesis 
defects the restoration of Cr levels in brain by exogenous supplementation is 
a process which proceeds very slowly and requires high Cr doses (Stöckler, 
Hanefeld, and Frahm 1996; Leuzzi et al. 2000). Moreover, some studies in 
cultured astrocytes measured low expression levels of CrT in brain, but 
literature about this issue is conflicting. If CrT expression were low in brain, 
as the above studies would suggest, it would be difficult to explain how CrT 
deficiency leads to a severe impairment of brain Cr content and to a severe 
disorder. In order to reconcile these contrasting observations, different 
theories have been advanced. 
The neuron-glial relationship hypothesis is based upon the preferential 
expression of GAMT in oligodendrocytes (Tachikawa et al., 2004) and 
predicts that Cr is mainly produced in glial cells and then transferred to 
neurons by means of the CrT. However, expression of both biosynthetic 
enzymes was described in neuron and glial cultures in some studies 
(Carducci et al. 2012; Braissant et al. 2001), challenging this hypothesis. 
The dissociation hypothesis states that AGAT and GAMT are 
expressed in many different brain cell types but rarely co-expressed in the 
same cells and, thus, the intermediate metabolite GAA must be transported 
by means of the CrT from one cell to another. However, this would lead to 
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high levels of toxic metabolite GAA in CrT defects (as observed in defects of 
GAMT) that are not observed (van de Kamp et al. 2012). 
The observation that, in CrT defects, Cr concentration is normal or 
even high in CSF, could be consistent with the hypothesis that a mechanism 
of Cr reuptake is lacking in this disorder (van de Kamp et al. 2013). CrT is 
member of a family of neurotransmitter transporters responsible for the 
reuptake of serotonin and dopamine, and defects of these transporters cause a 
biochemical phenotype similar to what observed in CrT defects (low 
intracellular metabolite concentration and high extracellular concentration). 
In vitro data show that hippocampal neurons release about 35% of their Cr 
content in 1-2 hours (Dodd et al., 2010). These observations, and further data 
regarding the restricted synthesis capability of Cr in neurons and glia 
(Carducci et al., 2012) suggest that one fundamental mechanism of Cr 
provision in brain cells is the reuptake, making the CrT a pivotal device in Cr 
metabolism and leading to the reuptake failure hypothesis as mechanism of 
Cr deficiency in CCDS1. 
It is well possible that the biochemical picture is more complex and 
most of the mechanisms described could be implicated in the 
pathophysiology. 
The defects of Cr synthesis can be treated with variable success. 
Supplementation of Cr with ornithine, accompanied by arginine restriction in 
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GAMT defects, proved useful in both AGAT and GAMT-defects, with at 
least partial restoration of cerebral Cr content and improvement of the 
clinical picture. In some cases, when the therapy started very early, an almost 
normal development was observed (Edvardson et al., 2010; Ndika et al., 
2012; Nouioua et al., 2013). 
On the contrary, the defects of Cr transporter cannot be successfully 
treated by Cr supplementation, as proven by many studies (Bizzi et al., 2002; 
Anselm et al., 2006; Póo-Argüelles et al., 2006). Arginine supplementation 
can increase, in vitro, the synthesis of Cr (Leuzzi et al. 2008) but showed 
only mild improved in some patients (Chilosi et al. 2008; Chilosi et al. 2012; 
Mercimek-Mahmutoglu et al. 2010). 
A way to bypass the blood brain barrier (BBB) could exploit lipophilic 
derivatives of Cr. Many molecules were tested (creatine-benzyl-ester, 
phosphocreatine-Mg-complex acetate, creatine-ethyl-ester, dodecyl-creatine-
ester) and some of them led to an increase in Cr levels in mouse or human 
brain cells cultures (Lunardi et al., 2006; Perasso et al., 2009; Fons et al., 
2010). These compounds tend to be degraded very early and no effect was 
found when tested in patients (Fons et al., 2010). 
Cyclocreatine (cycloCr) is a Cr analog less polar than Cr itself, which 
showed some improvement in mouse models and uptake in cell cultures after 
blocking the Cr transporter (Kurosawa et al., 2012; Enrico et al., 2013). The 
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kinetics of the phosphorylation of cycloCr is different compared to Cr and 
this could limit its usefulness (Walker, 1979). Further studies are thus 
necessary to assess the efficacy of this derivative. 
CCDS1 is therefore a disorder for which an effective treatment is still 
missing. The etiology of the disease, the lack of a transporter, could represent 
an obstacle difficult to circumvent with simple replacement therapy and, 
therefore, more sophisticated approaches could probably be required. 
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MOUSE MODELS OF CCDS1 
In our laboratory two different mouse lines are available to study 
CCDS1 pathophysiology and test putative treatment strategies. The first 
model is a ubiquitous model carrying a loss-of-function deletion of exons 5 – 
7 in the Slc68a gene. The second model is a conditional knock-out (KO) in 
which the expression of the CrT is impaired only in cells derived by neuronal 
precursors (i.e. neurons and glia) by crossing a floxed CrT line with a line 
expressing Cre-recombinase under the promoter of the Nestin gene (see 
Meterials and Methods). 
Other lines are available in other laboratories. One is a ubiquitous KO 
model generated by deletion of exons 2 – 4 in the Slc6a8 gene. Two other 
lines are conditional KO: one using a Ca2+/calmodulin-dependent protein 
kinase II (CaMKII) promoter to drive Cre-recombinase expression in order to 
achieve a CrT deletion only in postnatal forebrain excitatory neurons; another 
model has been created by crossing floxed Slc6a8 mice with Nestin-cre mice 
(Udobi et al., 2018), similarly to our conditional model. 
The following sections will report preliminary findings drawn by the 
ubiquitous KO model present in our facility (Baroncelli et al., 2014) because 
it is the same adopted for the present work. These findings were the state of 
knowledge about the characterization of this model from which the present 
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study started. Where differences have been found between the current model 
and the other ones, appropriate comments and interpretations will be 
provided. The detailed description of the experiments from which these 
findings are drawn can be found in the Material and Methods section. 
CREATINE CONCENTRATIONS AND BODY WEIGHT  
KO mice had a reduced Cr concentration in the brain, in both cortex 
and hippocampus, and in muscle, heart and kidney compared to wild-type 
(WT) littermates. 
The general appearance of KO mice was normal except for reduced 
body growth: at post-natal day (P) 60 the weight of KO was lower than WT. 
BEHAVIORAL TESTS 
To test general locomotor activity and anxiety-related behavior the 
open field arena was used. Both WT and KO mice spent more time in 
peripheral regions avoiding the center. No difference was found in the 
amount of time spent in periphery, in motion speed and in total distance 
walked between the two genotypes.  
Declarative memory was assessed by using object recognition test 
(ORT) which evaluates the capacity of recognizing a familiar object from a 
novel one. Both experimental groups explored the objects for the same 
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amount of time during the sample phase, whereas during the test phase at 24 
h, WT showed higher preference for the novel object compared to KO. 
Spatial working memory was evaluated by measuring the rate of 
spontaneous alternation in the Y maze. Both groups explored all the three 
arms of the maze without any difference in the total number of entries and 
any bias for one of the arms, indicating that general exploratory behavior was 
preserved in KO. The alternation rate was at chance level for KO, compared 
to the high alternation observed in the WT, showing a specific mnestic 
alteration. 
The Morris water maze (MWM) was used to assess spatial learning 
and memory. Lower swimming speed was detected in KO, and the 
performance was thus expressed in terms of distance swum to find the hidden 
platform. During the training phase, the distance covered to locate the 
platform was longer in KO compared to WT in the last three days. In order to 
evaluate the strength of learning and to discriminate between spatial and non-
spatial strategies to find the platform, on the last day the platform was 
removed and the time spent in the quadrant where the platform had 
previously been located was measured. WT mice spent more time in the 
target quadrant whereas KO showed no significant preference. 
General locomotor activity can also be assessed in a non-aversive 
environment (compared to the open filed arena which has an aversive 
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component) simply measuring home-cage locomotor activity. In this context 
KO showed decreased activity during night period compared to WT. The 
day-time activity was normal. 
The KO model used seems to recapitulate well the genetic and 
neurochemical features of patients affected by CCDS1. A remarkable 
difference compared to human is the finding of reduced Cr levels in KO mice 
muscle which is not observed in patients. This finding is not an idiosyncrasy 
of the specific model because it is shared by the other ubiquitous model 
(Russell et al., 2014), indicating that it is an intrinsic difference between 
mouse and human physiology. Consistent with muscle Cr impairment, motor 
performances were impaired in KO mice, as described above.  
Because of the differences found in motor and muscle performances 
between mice and patients, another model of CrT defect is described in 
literature in which the CrT has been knocked-out only in forebrain excitatory 
neurons. Despite the fact that this model shows alterations consistent with 
those observed in patients and without muscle involvement, this conditional 
model has an intrinsic strong limitation and cannot precisely recapitulate the 
pathophysiology of the brain involvement in CrT defect: CrT expression in 
inhibitory interneurons is preserved in this conditional model but, as already 
cited before, it is very high in at least a subclass of this cell type (namely, 
fast-spiking PV+ interneurons) in physiological conditions, meaning that CrT 
must hold an important role in PV+ neurons physiology. Sparing CrT 
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expression in inhibitory neurons can thus lead to a huge bias in the results 
and conclusions obtained from this model. 
To preserve muscular function, in order to recapitulate patients’ 
phenotype, conditional models in which the CrT is selectively disrupted 
selectively in all CNS cells, neurons and glia, can be very useful to dissect 
the many pathogenetic events of CCDS1. 
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AIM OF THE STUDY 
CCDS1 is a severe disorder with no effective treatment currently 
available and with high negative impact on life quality and expectancy of 
patients, as well as their families’ life quality. Social impacts are great too, 
due to the requirement for long health assistance, with huge economic 
burden.  
Valid therapeutic options can only come from a deep understanding of 
etiology and pathophysiology of this disorder. The little knowledge about the 
mechanisms and the effects of Cr deficiency on neural circuits stems, to 
some extent, from the paucity of studies on animal models. Two germline 
murine models of CCDS1 and one model of GAMT deficiency were 
available when the current project started and they were analyzed only in 
some behavioral domains and at neurochemical level, while studies on 
AGAT deficient mice were limited to metabolic effects of Cr deficiency 
(Choe et al., 2013). Learning and memory deficits, impaired motor activity 
and Cr depletion in the brain and muscles have been reported in GAMT and 
CrT models in the adult age (Torremans et al., 2005; Skelton et al., 2011; 
Baroncelli et al., 2014). However, little is known about the presence of 
autistic-like behavioral features and the onset and progression of the 
phenotype. 
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Furthermore, a growing number of studies showed that extraneural 
dysfunctions could underlie behavioral deficits in other mouse models of 
neurodevelopmental disorders (Depino, 2013; Sherwin, Dinan and Cryan, 
2018). However, no thorough assessment exists about this aspect in Cr 
deficiency disorders, causing a limited understanding of the relative 
contributions of periphery in CCDS1 pathophysiology. 
In order to fill these gaps and to dissect the molecular mechanisms of 
the pathophysiology of CrT defects, we took advantages of two different 
transgenic mouse lines, a ubiquitous one in which CrT is defective in all 
body cells, and a conditional one in which CrT expression is only impaired in 
cells derived from neuronal and glial precursors, i.e. only in CNS cells. The 
latter model allowed us to recapitulate better the phenotype observed in 
human patients in which muscle involvement is only a rare finding or at a 
limited extent, and it also proved invaluable in discriminating between neural 
and extraneural contributions to the pathophysiology of CCDS1. 
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MATERIAL AND METODHS 
ANIMALS 
As CrT deficiency is an X-linked pathology, male mice were selected 
for this study. CrT-/y and CrT+/y mice on a C57BL/6 J background were 
generated as described previously (Baroncelli et al., 2014). Animals were 
maintained at 22 °C under a 12-h light–dark cycle (average illumination 
levels of 1.2 cd/m2). Food (4RF25 GLP Certificate, Mucedola) and water 
were available ad libitum. To target CrT deletion to neuronal and glial cells 
of the central nervous system we used a mouse (Tronche et al., 1999) 
expressing Cre-recombinase under the Nestin promoter (Nestin:Cre). CrT+/fl 
females were crossed with Nestin:Cre male mice to generate a mouse line 
carrying the floxed CrT and Nestin:Cre alleles. Mice with three genotypes 
were used as experimental animals: mice carrying the brain specific deletion 
of CrT (Nestin:Cre-CrT-/y, nes-CrT-/y), mice expressing the floxed allele but 
not Cre-recombinase (CrTfl/y), and mice expressing Cre-recombinase but not 
carrying the floxed allele (Nestin:Cre-CrT+/y, nes-CrT+/y). These genotypes 
were obtained in the same litters. Since CrTfl/y mice did not display any 
difference in Cr levels with respect to nes-CrT+/y animals, we performed 
behavioral and anatomical investigation only in the other two experimental 
groups. All experiments were carried out in accordance with the European 
Communities Council Directive of 24 November 1986 (86/609/EEC) and 
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were approved by the Italian Ministry of Health (authorization number 
259/2016-PR). 
DETECTION OF SLC6A8 MUTATION BY PCR 
Genomic DNA was isolated from mouse tail using a kit, and the 
protocol suggested by the manufacturer (DNeasy Blood & Tissue Kit, 
Qiagen, USA). DNA was amplified for CrT mutant and wild-type alleles 
using a standard polymerase chain reaction (PCR) protocol with the 
following primers: F:AGGTTTCCTCAGGTTATAGAGA; 
R:CCCTAGGTGTATCTAACATC; R1: TCGTGGTATCGTTATGCGCC. 
Primers for Cre recombinase expression were: F: 
AACGCACTGATTTCGACC; R: CAACACCATTTTTTCTGACCC. For 
PCR amplification, we used 300 ng of DNA in a 25 µl reaction volume 
containing 0.2mM of each dNTP, 2 µM of F primer, 1 µM of R primer, 1 µM 
of R1 primer and 0.5 U/µl Red Taq DNA polymerase (Sigma-Aldrich, Italy). 
The PCR conditions were as follows: 94 °C for 4 min followed by 37 
cycles at 94 °C for 30 s, 58 °C for 30 s, 72 °C for 40 s and a final extension at 
72 °C for 7 min. Amplicons were separated using 2% agarose gel and 
visualized under UV light after staining with Green Gel Plus (Fisher 
Molecular Biology, Rome, Italy). Amplicon sizes were: WT allele = 462 bp; 
mutant allele = 371 bp; Cre allele = 310 bp. 
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BEHAVIORAL TESTING 
The testing order for behavioral assessment performed in the same 
animals consisted of: open field (1 day duration), ORT at 1h (1 day), ORT at 
24h (3 days), Y maze (1 day), MWM with hidden platform (7 days), rotarod 
(1 day), three chamber social test (1 day) and self-grooming (1 day). The 
mice were tested on one task at a time with the next behavioral test starting at 
least 1 day after the completion of the previous one. While open field, ORT, 
Y maze, rotarod and self-grooming were longitudinally administered to the 
same animals, MWM was performed in separate groups of animals at the 
different ages tested. Y maze has been also used to test cognitive functions in 
juvenile animals (P28). 
Social behavior has been tested only in 6-month old animals. In order 
to reduce the circadian effects, behavioral tests were performed during the 
same time interval each day (2:00 PM – 6:00 PM; light phase). All 
behavioral tests were conducted in blind with respect to the genotype of 
animals. Animals not performing the task required were excluded from the 
analysis. Mice were weighed at the end of experiments. 
OPEN FIELD AND OBJECT RECOGNITION TEST (ORT) 
The apparatus consisted of a square arena (60 x 60 x 30 cm) 
constructed in polyvinyl chloride with black walls and a white floor. The 
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mice received one session of 10-min duration in the empty arena to habituate 
them to the apparatus and test room. Animal position was continuously 
recorded by a video tracking system (Noldus Ethovision XT). In the 
recording software an area corresponding to the center of the arena (a central 
square 30 x 30 cm), and a peripheral region (corresponding to the remaining 
portion of the arena) were defined. The total movement of the animal and the 
time spent in the center or in the periphery area were automatically 
computed. Mouse activity during this habituation session was analyzed for 
evaluating the behavior in the open field arena. The ORT consisted of two 
phases: sample and testing phase. During the sample phase, two identical 
objects were placed in diagonally opposite corners of the arena, 
approximately 6 cm from the walls, and mice were allowed 10 min to explore 
the objects, then they were returned to their cage. The objects to be 
discriminated were made of plastic, metal, or glass material and were too 
heavy to be displaced by the mice. The testing phase was performed either 1h 
or 24h after the sample phase. One of the two familiar objects was replaced 
with a new one, while the other object was replaced by an identical copy. The 
objects were placed in the same locations as the previous ones. The mice 
were allowed to explore objects for 5 min. To avoid possible preferences for 
one of two objects, the choice of the new and old object and the position of 
the new one were randomized among animals. The amount of time spent 
exploring each object (nose sniffing and head orientation within < 1.0 cm) 
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was recorded and evaluated by the experimenter blind to the mouse 
genotype. Arena and objects were cleaned with 10% ethanol between trials to 
stop the build-up of olfactory cues. Mice exploring the two objects for less 
than 10 s during the sample phase were excluded from testing. A 
discrimination index was computed as DI = (T new – T old)/(T new + T old), 
where T new is the time spent exploring the new object, and T old is the time 
spent exploring the old one (Baroncelli et al., 2014). 
Y MAZE SPONTANEOUS ALTERNATION 
We used a Y-shaped maze with three symmetrical grey solid plastic 
arms at a 120-degree angle (26 cm length, 10 cm width and 15 cm height). 
Mice were placed in the center of the maze and allowed to freely explore the 
maze for 8 minutes. The apparatus was cleaned with 10% ethanol between 
trials to avoid the build-up of odor traces. All sessions were video-recorded 
(Noldus Ethovision XT) for offline blind analysis. The arm entry was defined 
as all four limbs within the arm. A triad was defined as a set of three arm 
entries, when each entry was to a different arm of the maze. The number of 
arm entries and the number of triads were recorded in order to calculate the 
alternation percentage, generated by dividing the number of triads by the 
number of possible alternations and then multiplying by 100 (Baroncelli et 
al., 2014). 
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MORRIS WATER MAZE 
Mice were trained for four trials per day and for a total of 7 days 
(Baroncelli et al., 2014) in a circular water tank, made from grey 
polypropylene (diameter: 120 cm; height: 40 cm), filled to a depth of 25 cm 
with water (23 °C) rendered opaque by the addition of a non-toxic white 
paint. Four positions around the edge of the tank were arbitrarily designated 
North (N), South (S), East (E) and West (W), which provided four alternative 
start positions and also defined the division of the tank into four quadrants, 
i.e. NE, SE, SW and NW. A square clear Perspex escape platform (11 x 11 
cm) was submerged 0.5 cm below the water surface and placed at the 
midpoint of one of the four quadrants. The hidden platform remained in the 
same quadrant during training, while the starting positions (N, S, E or W) 
were randomized across trials. The pool was situated in a room containing 
extra-maze cues that provide specific visual reference points for locating the 
submerged platform. Mice were allowed up to 60 s to locate the escape 
platform, and their swimming paths were automatically recorded by the 
Noldus Ethovision system. If the mouse failed to reach the platform within 
60 s, the trial was terminated and the mouse was guided onto the platform for 
15 s. On the last trial of the last training day, mice received a probe trial, 
during which the escape platform was removed from the tank and the 
swimming paths were recorded over 60 s while mice searched for the missing 
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platform. The swimming paths were recorded and analyzed with the Noldus 
Ethovision system. 
ROTAROD AND GRIP STRENGTH 
Motor coordination and abilities were assessed using the rotarod test 
as described by Lonetti and colleagues (Lonetti et al., 2010). Animals were 
placed on a drum with increasing rotation speed from 4 to 40 rpm. The time 
spent on the drum was recorded by an automated unit, which stops as the 
mouse fall. Motor abilities were assessed by conducting the test for four 
consecutive times with an interval of 5 min in the same day. In the grip 
strength test a peak amplifier automatically measures the peak pull-force 
achieved by animals’ forelimbs. 
THREE-CHAMBER SOCIAL TEST 
The three-chamber paradigm test has been successfully employed to 
study sociability and preference for social novelty in several mutant mouse 
lines. ‘Sociability’ is defined as a propensity to spend time with a 
conspecific, as compared to time spent alone in an identical but empty 
chamber; ‘preference for social novelty’ is defined as propensity to spend 
time with a new mouse rather than with a familiar mouse (Moy et al., 2004). 
We adapted the protocol reported by Kaidanovich-Beilin and colleagues  
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(Kaidanovich-Beilin et al., 2011). The apparatus consisted in a rectangular, 
three-chamber box made from clear Plexiglas (72 cm wide x 50 cm length x 
33 high). Each chamber is 24 x 50 cm and the dividing walls are made from 
clear Plexiglas, with an open middle section, which allows free access to 
each chamber. Two identical, wire cup-like containers with removable lids 
were placed inside the apparatus, one in each side chamber. Each container 
was made of metal wires allowing for air exchange between the interior and 
exterior of the cup but small enough to prevent direct physical interactions 
between the inside animal and the subject mouse. Two classes of mouse were 
used in this experiment, one acting as a control, naïve animal, while the other 
is the test subject. The control mouse was a mouse of the same background, 
age, gender and weight, without any prior contact with the subject mouse. 
Two control mice were required per experiment, one used for session I 
(Stranger 1) and another for session II (Stranger 2). The same control mice 
were used between trials. Control mice were gradually habituated to wire-cup 
housing in the three-chamber box for 4 days (30 min per day) before the 
starting of test session. After 10 min of habituation in the arena with empty 
wire cups of the subject mouse, we placed Stranger 1 inside one of the wire 
cups. The subject mice were allowed to explore each of the three chambers 
for 10 min (session I). Animal position was continuously recorded by a video 
tracking system (Noldus Ethovision XT). The amount of time spent 
exploring each wire cup was recorded and evaluated by the experimenter 
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blind to the mouse genotype. A discrimination index was computed as DI = 
(Tsoc – Tobj) / (Tsoc + Tobj), where Tsoc is the time spent exploring the cup 
housing the Stranger 1, and Tobj is the time spent exploring the other cup. In 
session II we placed Stranger 2 inside the wire cup in the opposite side 
chamber. Duration of session II was 10 min and we calculated the same DI 
described above, differentiating the exploration time of the subject mouse 
between Stranger 1 and Stranger 2. The placement of Stranger 1 and Stranger 
2 in the left or right side of the box was randomized between trials. Arena 
and wire cups were cleaned with 10% ethanol between trials to prevent 
olfactory cue bias. 
SELF-GROOMING 
Mice were scored for spontaneous grooming behaviors as described 
earlier (McFarlane et al., 2008). Each mouse was placed individually into a 
clean, empty, standard mouse cage (27 cm length x 20 cm wide x 15 cm 
high) without bedding. Animal behaviors were videotaped for 20 min. After 
a 10-min habituation period in the test cage, each mouse was scored with a 
stopwatch for 10 min for cumulative time spent grooming all body regions. 
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BIOCHEMICAL ANALYSIS 
For Cr and GAA assay, mouse tissues, immediately frozen on dry ice 
and stored at -80°C until the analysis, were homogenized in 0.7 ml PBS 
buffer (Sigma-Aldrich, Italy) at 4°C using an ultrasonic disruptor (Microson 
Heat System, NY, USA) for brain or a glass manual homogenizer (VWR, 
Italy) for kidney, heart and muscle. After centrifugation (600 x g for 10 min 
at 4°C) an aliquot of the homogenate (50 ml) was assayed for protein content 
and the supernatant used for Cr assay as previously described (Alessandrì et 
al., 2005). Briefly, 50 ml of saturated sodium hydrogen carbonate and 50 ml 
of a mixture containing 2-phenylbutyric acid (I.S.) in toluene (6.09 mmol/l; 
Sigma-Aldrich, Italy) were added to 200 ml of homogenate or to 100 ml of 
serum and urine, respectively. After adding 1ml of toluene and 50 ml of 
hexafluoro-2,4-pentanedione (Sigma-Aldrich, Italy) to form 
bistrifluoromethyl-pyrimidine derivatives, the mixture was stirred overnight 
at 80°C. The organic layer was centrifuged, dried under nitrogen and 2 ml of 
the residue derivatized at room temperature with 100 ml of BSTFA+TMCS 
(Sigma-Aldrich, Italy) injected into the Gas Chromatography/Mass 
Spectrometry (GC/MS) instrument. GC analyses were performed using an 
Agilent 6890N GC equipped with an HP5MS capillary column (0.25 mm x 
30 m, film thickness 0.25 mm) and an Agilent mass spectrometer 5973N 
(Agilent Technologies, Italy). The mass spectrometer was set in EI-single ion 
monitoring mode (SIM). The ions with m/z of 192 for I.S., 258 for Cr and 
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225 for GAA were used for calculation of the metabolites, using standard 
curves ranging 5–90 mmol/l and 0.30–6 mmol/l for Cr and GAA, 
respectively. Data were processed by the G1701DA MSD ChemStation 
software. All the aqueous solutions were prepared using ultrapure water 
produced by a Millipore system. 
IMMUNOHISTOCHEMISTRY 
Mice were perfused transcardially with 4% paraformaldehyde in 
phosphate buffer. Brains were post-fixed and impregnated with 30% sucrose 
in phosphate buffered saline (PBS). Coronal brain sections (40 mm thick) 
were cut on a freezing microtome and collected in PBS before being 
processed for immunohistochemistry. After a blocking step, free-floating 
slices were incubated O/N at 4°C in a solution of primary antibody (NeuN, 
Millipore, 1:500; Ki67, Abcam, 1:400; DCX, Abcam, 1:200; vGlut1, 
Synaptic System, 1:500; vGAT, Synaptic System, 1:1,000; Iba-1, Wako, 
1:400) and antigen-antibody interaction was revealed with suitable Alexa 
Fluor-conjugated secondary antibodies (1:400, Invitrogen). Immunostaining 
for Ki67 involved an additional treatment with sodium citrate for antigen 
retrieval. Sections were then counterstained with Hoechst dye (1:500, 
Sigma), mounted on microscope slides and coverslipped using Vectashield 
mounting medium for fluorescence (Vector Laboratories Inc.). 
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IMAGE ANALYSIS 
NeuN and Iba1: to quantify the density of neuronal and microglial 
cells in the cerebral cortex we used the StereoInvestigator software 
(MicroBrightField) equipped with motorized X–Y sensitive stage and video 
camera connected to a computerized image analysis system. NeuN-positive 
cells were counted using 20x magnification and sampling boxes (250 x 250 x 
40 µm) located in both superficial and deep layers of PFC and ACC cortex. 
Iba1-positive cells were counted using 40x magnification and sampling 
boxes (250 x 250 x 40 µm) located in both superficial and deep layers of PFC 
cortex. Cell density was calculated by averaging values obtained from at least 
6-8 counting boxes per animal.  
Ki67 and DCX: examination of Ki67 and DCX-positively labelled 
cells was confined to the hippocampal dentate gyrus (DG), specifically to the 
granule cell layer (GCL) and the subgranular zone of the hippocampus 
defined as a two-cell body-wide zone along the border between the GCL and 
hilus. Quantification of Ki67 or DCX-immunoreactive cells was conducted 
from 1-in-6 series of immunolabelled sections using 20x magnification and 
spanning the rostrocaudal extent of DG. All immunostained sections were 
analyzed using the StereoInvestigator software. The reference volume was 
determined as the sum of the traced areas multiplied by the distance between 
the sampled sections. Densities of immunopositive cells were then calculated 
by dividing the number of positive cells by the reference volume. Numbers 
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of positively labelled neurons were normalized as density per unit of volume 
(mm3).  
vGlut1 and vGAT: to quantify the density of vGlut1- and vGAT-
positive puncta, the parameters of acquisition (laser intensity, gain, offset) 
were optimized at the beginning of the acquisition and then held constant 
throughout image acquisition. All sections were acquired in random order in 
a single session to minimize fluctuation in laser output and degradation of 
fluorescence. We imaged superficial and deep layers of PFC and ACC on a 
Zeiss laser-scanning Apotome microscope using a 63x oil immersion 
objective. For each section, we imaged serial optical sections at 0.33 µm 
intervals for a total of at least 15 optical sections (5 µm). From each animal 
we imaged 6 sections (3 in superficial layers and 3 in deep layers). Maximum 
intensity projections (MIPs) were generated from the group of 5 consecutive 
sections yielding the higher mean pixel intensity. These MIPs were imported 
in ImageJ and quantified using Puncta analyzer plugin (Ippolito and Eroglu, 
2010). The number of positive puncta was measured within the entire 
acquired area. 
DETERMINATION OF LIPOFUSCIN ACCUMULATION BY 
AUTOFLUORESCENCE 
Coronal brain sections were mounted on microscope slides and 
coverslipped using Vectashield mounting medium for fluorescence (Vector 
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Laboratories Inc.). We imaged hippocampal DG on a Zeiss laser-scanning 
Apotome microscope using a 40x oil immersion objective. The parameters of 
acquisition were optimized at the beginning of the experiment and then held 
constant. Lipofuscin level was measured as the presence of autofluorescence 
at 550 nm in the region of interest. For each section, we imaged serial optical 
sections at 0.5 µm intervals for a total of at least 80 optical sections (40 µm). 
From each animal we imaged 3 – 4 sections. MIPs were generated from the 
group of 5 consecutive sections yielding the higher mean pixel intensity. 
These MIPs were imported in ImageJ and quantified using Threshold plugin. 
The area of positive puncta and mean pixel intensity were measured within 
the entire acquired area.  
PATCH CLAMP RECORDINGS 
Mice (aged P30 - 40) were deeply anesthetized with isoflurane 
(Baxter) then quickly decapitated. The brain was rapidly removed, and 
coronal sections (225 μm thick) of the primary visual cortex (V1) were 
obtained by cutting in a solution bubbled with 99% O2 and containing (in 
mM): 240 sucrose, 2.5 KCl, 1.2 MgCl2, 2.4 CaCl2, 1.2 NaH2PO4, 15 
NaHCO3, 10 HEPES and 5 Glucose, at pH 7.4, using a Leica VT1000S 
vibratome. Immediately after sectioning, slices were transferred in recording 
artificial cerebro-spinal fluid (aCSF) bubbled with 99% O2, containing (in 
mM): 126 NaCl, 2.4 sucrose, 2.5 KCl, 2.4 MgCl2, 1.2 CaCl2, 1.2 NaH2PO4, 
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15 NaHCO3, 10 HEPES and 5 Glucose, at pH 7.4, and maintained at 35°C 
for 20 – 25 min then transferred at room temperature (RT) for a further 1 h 
before recordings were started. Somatic whole-cell recordings were obtained 
from pyramidal-shaped neurons in layer 4 of V1. Intracellular solution for 
miniature inhibitory post-synaptic potential (mIPSCs) in current clamp 
recordings contained (in mM): 10 K-Gluconate, 130 KCl, 10 Hepes, 1 
EGTA, 0.3 CaCl2, 1 MgCl2, 4 MgATP, 0.3 NaGTP, 5 Phosphocreatine, at pH 
7.3. Phosphocreatine was used only for the recordings of cells from WT 
mice, whereas KO cells were recorded without phosphocreatine, in order to 
simulate better the natural condition of Cr deficiency. The osmolarity of the 
intracellular solution was adjusted to 280 – 290 mOsm/l. For mIPSCs, cells 
were voltage-clamped at -80 mV by a Multiclamp 700A computer-controlled 
amplifier (Molecular Devices), sampled at 10 kHz and low-pass filtered at 2 
kHz. Synaptic transmission was blocked by 1 μM tetrodotoxin (TTX), 
glutamate AMPA receptors were blocked by 10 µM 6,7-dinitroquinoxaline-
2,3-dione (DNQX) and glutamate NMDA receptors were blocked by 50 μM 
(2R)-amino-5-phosphonovaleric acid (APV). Glass pipette electrodes (2 to 4 
MΩ resistance when filled with internal solutions) were pulled from 
borosilicate capillaries (World Precision Instruments) using a Sutter P97 
Flame Brown Puller (Sutter Instruments). Data acquisition and analysis was 
performed by using Clampex 8.2, Clampfit 10.3 (Molecular Devices) and 
Mini Analysis Program (Synaptosoft Inc.). Recordings in which access 
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resistance (Ra) was higher than 50 MΩ or in which a variation of Ra > 20% 
was observed between the beginning and the end of the recording were 
discarded. 
PROTEOMIC ANALYSIS OF MITOCHONDRIA 
Materials used: Iodoacetamide, dithiothreitol (DTT), 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), urea, 
thiourea, glycerol, sodium dodecyl sulfate (SDS), 
tetramethylethylenediamine (TEMED), ammonium persulfate (APS), glycine 
and 30% acrylamide-N,N,N bisacrylamide were acquired from Applichem 
(Germany). IPGs pH 3–10 NL, IPG-buffer 3–10NL and dry stripcover fluid 
were purchased from GE Health Care Europe (Uppsala, Sweden). Enhanced 
chemiluminescence (ECL) detection system was purchased from 
PerkinElmer (MA, USA). Anti-cofilin-1 (CFL1), anti-peptidyl-prolyl-cis-
trans isomerase A (PPIA), anti-superoxide dismutase 1 (SOD1) and anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies were 
purchased from Cell Signaling Technology, Inc. (MA, USA). Anti-
peroxiredoxin 6 (PRDX6) antibody and was purchased from Santa Cruz 
Biotechnologies (TX, USA). Anti-peroxiredoxin 5 (PRDX5) antibody was 
acquired from R&D Systems Biotechne (MN, USA) and anti-ubiquinol-
cytochrome c reductase binding protein  (UQCRB) antibody was purchased 
from GeneTex Inc.(CA, USA) antibodies were purchased from Thermo-
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Fisher Scientific Inc. (MA, USA). A donkey anti-rabbit secondary antibody 
horseradish peroxidase (HRP)-conjugated was purchased from Stressgen 
(Belgium) while a donkey anti-goat secondary antibody HRP-conjugated and 
a  goat anti-mouse secondary antibody HRP-conjugated were acquired from 
Santa-Cruz Biotechnology (TX, USA). Ruthenium II tris (bathophenantroline 
disulfonate) tetrasodium salt stain was purchased from Cyanagen All other 
reagents were purchased from standard commercial sources and were of the 
highest grade available. 
Enriched Mitochondria preparations: for proteomic studies CrT+/y and 
CrT-/y P30 mice whole brains were immediately removed and processed to 
obtain mitochondrial enriched fractions. Briefly, whole brain was weighed, 
dissected on ice and homogenized in 10 volumes (w/V) isolation buffer (IB) 
(250 mM sucrose, 10 mM HEPES, 1 mM EDTA, pH 7.5) using a Teflon-
glass homogenizer (15 strokes). Sample was centrifuged at 1000 g for 10 min 
at 4°C and the resulting pellet, containing nuclei and unbroken cell, was 
further homogenized in IB and centrifuged at 1000 g for 10 min at 4°C. The 
resulting two supernatants were combined and centrifuged at 1000 g for 8 
min at 4°C to remove any nuclei and cellular debris. Then supernatant was 
centrifuged at 10000 g for 10 min at 4°C to obtain enriched mitochondrial 
fraction. Mitochondria were resuspended in IB and washed twice. Finally, a 
volume of IB, depending on size of pellet, was added to resuspend 
mitochondrial fraction. Protein amounts were carried out by Biorad-DC assay 
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using BSA as a standard. Mitochondria fractions were stored at -80°C until 
use.    
Two dimensional electrophoresis: 2DE was performed as previously 
described (Ciregia et al., 2013). Briefly, 250 µg of proteins were filled up to 
450 l in rehydration solution, following the protocol of Rabilloud adjusted 
for mitochondrial solubilitazion. Immobiline Dry-Strips, 18 cm linear 
gradient pH 3 - 10 were rehydrated overnight in the sample and then 
transferred to the Ettan IPGphor Cup Loading Manifold for 
isoelectrofocusing according to protocol previously described (Ciregia et al., 
2013). Then Immobiline strips were equilibrated and the second dimension 
(SDS-PAGE) was carried out by transferring proteins to 12% 
polyacrylamide, running overnight at 16 mA per gel at 10°C.  At the end of 
run, the gels were stained with Ruthenium II tris (bathophenantroline 
disulfonate) tetrasodium salt (RuBP). ImageQuant LAS4010 (GE Health 
Care) was used for the acquisition of images. The analysis of images was 
performed using Same Spot (v4.1, TotalLab; Newcastle Upon Tyne, UK) 
software. The spot volume ratios between KO and WT were calculated using 
the average spot normalized volume of the three biological replicates each 
performed in duplicate. The software included statistical analysis 
calculations.  The protein spots of interest were cut out from the gel and 
identified by LC-MS analysis. 
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Spot Digestion and Protein Identification: the gel pieces were washed 
twice with the wash buffer (25 mM NH4HCO3 in 50% acetonitrile (ACN)). 
Afterwards, proteins were reduced with 10 mM ditiothreitol (DTT) (45 min, 
56°C), and alkylated with 55 mM iodoacetamide (IAA) (30 min, RT, in the 
dark). After two washes with the wash buffer, spots were completely dried in 
a centrivap vacuum centrifuge. The dried pieces of gel were rehydrated for 
30 min at 4°C in 30 μL of trypsin porcine (Promega, Madison, WI, USA) 
solution (3 ng/μL in 100 mM NH4HCO3) and then incubated at 37°C 
overnight. The reaction was stopped by adding 10% trifluoroacetic acid 
(TFA). Samples were analyzed by LC-MS using a shorter chromatographic 
gradient and in autoMS mode. Each digested spot sample was analyzed by 
LC-MS/MS using a Proxeon EASY-nLCII (Thermo Fisher Scientific, Milan, 
Italy) chromatographic system coupled to a Maxis HD UHR-TOF (Bruker 
Daltonics GmbH, Bremen, Germany) mass spectrometer. Peptides were 
loaded on the EASY-Column TM C18 trapping column (2 cm L., 100 µm 
I.D, 5 µm ps, Thermo Fisher Scientific), and subsequently separated on an 
Acclaim PepMap100 C18 (75 µm I.D., 25 cm L, 5 µm ps, Thermo Fisher 
Scientific) nanoscale chromatographic column. The flow rate was set to 300 
nL/min and the gradient was from 2% to 20% of B in 12 min followed by 20 
to 45% in 9 min and from 45% to 90% in 2 min (total run time 35 min). 
Mobile phase A was 0.1% formic acid in H2O and mobile phase B was 0.1% 
formic acid in acetonitrile. The mass spectrometer, typically providing a 
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60,000 full width at half maximum (FMHW) resolution throughout the mass 
range, was equipped with a nanoESI spray source. The mass spectrometer 
was operated in Data Dependent Acquisition mode (DDA), using N2 as the 
collision gas for collision-induced dissociation (CID) fragmentation. 
Precursors in the range 400 to 2200 m/z (excluding 1220.0–1224.5 m/z) with 
a preferred charge state +2 to +5 and absolute intensity above 4706 counts 
were selected for fragmentation in a fixed cycle time of 3 s. After two 
spectra, the precursors were actively excluded from selection for 36 s. 
Isolation width and collision energy for MS/MS fragmentation were set 
according to the mass and charge state of the precursor ions (from 2+ to 5+ 
and from 21 to 55 eV). In-source reference lock mass (1221.9906 m/z) was 
acquired online throughout runs. 
The raw data were processed using PEAKS Studio v7.5 software 
(Bioinformatic Solutions Inc, Waterloo, ON, Canada) using the function 
“correct precursor only”. The mass lists were searched against the nextprot 
database including isoforms (version as of June 2017; 42,151 entries) using 
10 ppm and 0.05 Da as the highest error tolerances for parent and fragment 
ions, respectively. Carbamidomethylation of cysteines was selected as fixed 
modification and oxidation of methionines and deamidation of asparagine 
and glutamine as variable modifications allowing 2 missed cleavages. 
Western blot analysis: proteins of all WT and KO samples were  
separated by 1-D gel electrophoresis and then transferred onto nitrocellulose 
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membranes (0.2 mm) as previously described (Ciregia et al., 2013). PPIA, 
GAPDH and UQCRB antibodies have been used at 1:1000 dilution whereas 
SOD1 and PRDX6 have been used at 1:200 dilution. Finally PRDX5 has 
been used at concentration of 1 g/ml. HRP-goat anti-rabbit and HRP-goat 
anti-mouse secondary antibodies were used at 1:10000 dilution whereas 
HRP-anti-goat was used at 1:5000 dilution. Immunoblots were developed 
using the enhanced chemiluminescence detection system (ECL). The 
chemiluminescent images were acquired using LAS4010. The 
immunoreactive specific bands were quantified using Image Quant-L 
software.  In order to normalize the optical density of immunoreactive bands 
the optical density of total proteins was calculated. Therefore,  immediately 
after WB, the membranes were stained with 1 mM RuBP (Ciregia et al., 
2017). 
STATISTICAL ANALYSIS 
All statistical analyses were performed using SigmaStat Software. 
Differences between two groups were assessed with a two-tailed t test. The 
significance of factorial effects and differences among more than two groups 
were evaluated with ANOVA/RM ANOVA followed by Holm-Sidak test. 
Rank transformation was exploited for data not normally distributed. Mann-
Whitney test was used to analyze the distribution of frequency and amplitude 
of mIPSCs. For proteomic analysis of 2DE, a comparison among the 
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different treatments was performed. The significance of the differences of 
normalized volume for each spot was calculated by the software Same Spot 
including ANOVA test.  
The level of significance was p < 0.05. 
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RESULTS 
REDUCED BODY WEIGHT GROWTH IN CRT-/Y MICE 
A first clue indicating that CrT deficiency elicits age-related 
detrimental effects emerged from the general appearance of mutant animals. 
Mice were weighed at different ages and compared with WT littermates 
(Figure 4). Even though no particular problems of breeding were observed 
and the face of CrT-/y mice was normal till P40, CrT-/y animals (n = 12) 
showed a significantly reduced body weight compared to CrT+/y animals at 
P60, P100 and P180 (n = 13; Two-Way ANOVA on rank transformed data, p 
< 0.001 effect of genotype, p < 0.001 interaction between genotype and age; 
post hoc Holm-Sidak method, p = 0.092 at P40, p < 0.001 in all other 
comparisons). 
 
Figure 4. The weight of CrT-/y mice (n = 12) was significantly reduced compared to CrT+/y animals 
(n = 13) at P60, P100 and P180 (Two Way ANOVA on rank transformed data, post hoc Holm-
Sidak method). *** p < 0.001. Error bars: SEM. 
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AGE-RELATED DETERIORATION OF COGNITIVE FUNCTIONS IN CR 
DEFICIENCY CONDITIONS 
In a previous behavioral investigation performed at P40, it was 
highlighted that CrT-/y mice exhibit a general cognitive impairment across 
different learning and memory tests (Baroncelli et al., 2014). To understand 
whether a progressive deterioration of cognitive performance is present in 
CrT-/y mice, we studied four different stages: I) during the early brain 
development (P28 at the beginning of testing); II) during the late brain 
development (P40 at the beginning of testing); III) in the adult age (P100 at 
the beginning of testing) and IV) in the middle age (P180 at the beginning of 
testing). Interestingly, a progressive worsening of cognitive symptoms was 
detectable in CrT-/y mutant mice, suggesting that age is a key feature of Cr 
deficiency disease. 
Y MAZE 
We first analyzed the performance of CrT-/y animals at P28 using the 
Y maze spontaneous alternation, which is an optimal task for probing 
memory in juveniles (Figure 5A). Animals of both groups equally explored 
all the three arms of the maze. Indeed, no effect of genotype was detected for 
either the number of entries in the single arms of the maze (designated A, B, 
C) or the total number of arm entries, indicating that the exploratory 
disposition of mutant animals (n = 9) was not altered compared to WT 
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littermates (n = 11; Two-Way ANOVA on rank transformed data, post hoc 
Holm-Sidak method, p = 0.506, p = 0.941, p = 0.276, p = 0.391 respectively, 
Figure 5A). However, while in young WT mice alternation rate was about 
60% of total arm choices, in CrT-/y animals it dropped to the chance level 
(50%; Figure 5B), demonstrating that CrT disruption in the mouse model 
could reproduce the early pathological phenotype of CCDS1 patients. The 
same impairment was detected at P40, P100 and P180 with CrT-/y mice 
performing at chance level whereas WT age-matched controls showed 
significant spontaneous alternation (t-test, p < 0.01 for P40, p < 0.05 for P100 
and P180, Figure 6). These data also indicated that the spontaneous 
alternation paradigm cannot reveal age-dependent cognitive decline in CrT 
mutants because of the ceiling effect in the arm alternation deficit masking 
the effect of the age variable. 
 
Figure 5. Early deficiency of working memory in CrT-/y mice. (A) Schematic diagram of the Y 
maze apparatus. The mean number of entries in the single arms of the maze (A, B, C) and the total 
number of arm entries were comparable for the different experimental groups (Two-Way ANOVA 
on rank transformed data, post hoc Holm-Sidak method, p = 0.506, p = 0.941, p = 0.276, p = 0.391, 
respectively). (B) Alternation rate in the Y maze was significantly lower in CrT-/y mice (n = 9) 
compared to that recorded for CrT+/y littermates (n = 11; t test, p < 0.05) at P28. * p < 0.05. Error 
bars: SEM. 
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Figure 6. Impaired working memory in CrT-/y mice. Alternation rate in the Y maze was significantly 
lower in CrT-/y mice compared to that recorded for CrT+/y littermates at P40 (CrT+/y, n = 13, CrT-/y, n 
= 12; t-test, p < 0.01, panel A), P100 (CrT+/y, n = 13, CrT-/y, n = 12; t-test, p < 0.05, panel B) and 
P180 (CrT+/y, n = 9, CrT-/y, n = 7; t-test, p < 0.05, panel C). * p < 0.05; ** p < 0.01. Error bars: SEM. 
OBJECT RECOGNITION TEST (ORT)  
We assessed declarative memory abilities in the ORT, a test based on 
the spontaneous tendency of rodents to spend more time exploring a novel 
object than a familiar one. No difference in short-term recognition memory 
between P40 CrT-/y mice (n = 9) and age-matched WT animals (n = 7) could 
be detected (t-test, p = 0.285). In contrast, the discrimination index at 24h 
was significantly lower in mutant mice, indicating that their capacity to recall 
the familiar object was impaired (t-test, p < 0.05; Figure 7A). This memory 
deficit became more pronounced two months later (CrT-/y n = 11, CrT+/y n = 
10; P100, t-test, p < 0.01 at 24h; Figure 7B), eventually affecting both short- 
and long-term memories at P180. Indeed, at P180 CrT-/y mice showed a 
marked memory deficit both at 1- and 24-h interval between the sample and 
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the test phase with respect to CrT+/y mice (CrT-/y n = 10, CrT+/y n = 9; t-test, p 
< 0.05 for both comparisons; Figure 7C), indicating that the longer the time 
during which neural circuits are forced to work without Cr energy buffer the 
worse the cognitive performance of CrT-/y animals. 
 
Figure 7. Progressive impairment of object recognition memory in CrT-/y mice. Top, a schematic 
representation of the object recognition task. Histograms display object discrimination indexes of 
CrT+/y and CrT-/y during the testing phase performed after a delay of 1 and 24h since the sample 
phase at different ages. (A) P40. While both experimental groups can recognize the new object in the 
test at 1h (t-test, p = 0.285), a significantly lower discrimination index was found in CrT-/y mice (n = 
9) compared to CrT+/y animals (n = 7; t-test, p < 0.05). (B) P100. Even if still not significant, the 
recall capacity of CrT-/y animals at 1h was reduced (t-test, p = 0.242). At 24h, a t-test revealed that 
the performance of CrT-/y animals (n = 11) was strongly impaired with respect to controls (n = 10; p 
< 0.01). (C) P180. A significant deficit of both short (t-test, p < 0.05) and long-term (t-test, p < 0.05) 
memory was detected in mutant mice (n = 10) compared to controls (n = 9). * p < 0.05; ** p < 0.01. 
Error bars: SEM. 
MORRIS WATER MAZE (MWM) 
We further assessed memory abilities in the MWM, a cognitive 
paradigm that allows testing spatial learning and memory. The probe test 
highlighted a spatial memory impairment in Cr deficient mice at all the 
different ages tested: WT animals, indeed, spent significantly longer time in 
the quadrant where the platform was located during the training days (NE*; 
Two-Way RM ANOVA, post hoc Holm-Sidak method, p < 0.05 for all 
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comparisons), while mutant mice did not remember the location of the 
hidden platform and equally explored the four quadrants of the maze (Two-
Way RM ANOVA, post hoc Holm-Sidak method; Figure 8).  
The results obtained in the training phase of the MWM test, however, 
showed a clear progression of cognitive deficits in CrT-/y mice. Since a main 
effect of genotype was found on mean swimming speed recorded all along 
the training phase at the different ages tested (t-test, p < 0.05 (P40); Mann–
Whitney Rank Sum test, p < 0.05 (P100); t-test, p < 0.01 (P180); Figure 9), 
we analyzed the length of path covered to find the submerged platform. At 
P40 CrT-/y animals (n = 12) were able to learn the task as well as their age-
matched WT controls (n = 10): although the mean distance to locate the 
submerged platform on the last three days of training was longer in mutant 
mice compared to CrT+/y littermates (t-test, p < 0.05), they exhibited a 
progressive reduction of the path length similar to WT littermates (Two-Way 
RM ANOVA, p = 0.084 effect of genotype) with a significant difference 
between the two groups only at the day 5 of training (post hoc Holm-Sidak 
method, p < 0.05; Figure 10). The same was true in P100 animals (CrT-/y: n = 
8, CrT+/y: n = 7; Two-Way RM ANOVA on rank transformed data, p = 0.132 
effect of genotype, post hoc Holm-Sidak method, p < 0.05 at day 5; Figure 
10). In contrast, CrT-/y mice (n = 7) were significantly slower learners with 
respect to age-matched WT mice (n = 9) at P180 so much so that the distance 
to locate the platform was different between the two groups at days 3, 4, 5 
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and 6 of training (Two-Way RM ANOVA on rank transformed data, 
genotype, p < 0.001, interaction between genotype and day p < 0.001; post 
hoc Holm-Sidak method, p < 0.05 for day 3 and 6, p < 0.01 for day 4 and 5; 
Figure 10C). 
Figure 8. Spatial memory impairment in CrT-/y mice. A Two-Way RM ANOVA followed by Holm-
Sidak multiple comparison revealed that while CrT+/y spent significantly more time in the NE* 
quadrant than in the other ones, CrT-/y did not show any preference for the target quadrant at P40 
(CrT+/y, n = 10, CrT-/y, n = 12; panel A), P100 (CrT+/y, n = 7, CrT-/y, n = 8; panel B) and P180 
(CrT+/y, n = 9, CrT-/y, n = 7; Two-Way RM ANOVA, post hoc Holm-Sidak method, panel C). At all 
ages tested, the percentage of time spent in the target quadrant was shorter in CrT-/y mice than in the 
control group (Two-Way RM ANOVA, post hoc Holm-Sidak method, p < 0.05 at P40 and p < 0.01 
at P100 and P180). At P180, a significant difference was also detected in the percentage of time 
spent in the SO quadrant by CrT+/y and CrT-/y mice (p < 0.05). * p < 0.05; ** p < 0.01. Error bars: 
SEM. 
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Figure 9. Slower swimming velocity in CrT-/y mice. Mean swimming speed measured all along the 
training phase of the Morris water maze for CrT+/y and CrT-/y animals at P40 (CrT+/y, n = 10, CrT-/y, 
n = 12; panel A), P100 (CrT+/y, n = 7, CrT-/y, n = 8; panel B) and P180 (CrT+/y, n = 9, CrT-/y, n = 7; 
panel C). At all ages tested mutant mice resulted to be slower swimmers with respect to control 
littermates (t-test, p < 0.05 at P40 and p < 0.01 at P180; Mann-Whitney Rank Sum test, p < 0.05 at 
P100). * p < 0.05; ** p < 0.01. Error bars: SEM. 
 
Figure 10. CrT deletion progressively deteriorates spatial learning and memory in mutant mice. (A) 
Left, learning curves for CrT+/y (n = 10, white) and CrT-/y mice (n = 12, grey) at P40. A significant 
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difference was detected at day 5 (Two-Way RM ANOVA, post hoc Holm-Sidak method, p < 0.05). 
Right, histograms showing the mean swimming path covered to locate the submerged platform on 
the last three days of training for the two groups. A significant difference between CrT -/y and CrT+/y 
animals was present (t-test, p < 0.01). Representative examples of swimming path during the day 3 
of the training phase for a CrT+/y (top) and a CrT-/y mouse (bottom) are also reported. (B) Left, 
learning curves for CrT+/y (n = 7, white) and CrT-/y mice (n = 8, grey) at P100. A significant 
difference was detected at day 5 (Two-Way RM ANOVA, post hoc Holm-Sidak method, p < 0.05). 
Right, histograms showing the mean swimming path on the last three training days for the two 
groups. A significant difference between CrT+/y and CrT-/y animals was present (t-test, p < 0.05). 
Representative examples of swimming path during the day 3 of the training phase for a CrT+/y (top) 
and a CrT-/y mouse (bottom) are also reported. (C) Left, learning curves for CrT+/y (n = 9, white) 
and CrT-/y mice (n = 7, grey) at P180: mutant mice were poorer learners with respect to control 
littermates and a significant difference was detected at day 3, 4, 5 and 6 (Two-Way RM ANOVA 
on rank transformed data, post hoc Holm-Sidak method, p < 0.05 for day 3 and 6, p < 0.01 for day 4 
and 5). Right, histograms showing the mean swimming path on the last three days of training. A t-
test analysis showed a statistical difference between CrT+/y and CrT-/y animals (p < 0.01). 
Representative examples of swimming path during the day 3 of the training phase for a CrT+/y (top) 
and a CrT-/y mouse (bottom) are also depicted. * p < 0.05; # p < 0.01. Error bars: SEM. 
 
To further corroborate the hypothesis of a premature cognitive decline in CrT 
null mice, we compared the performance in the MWM of P180 CrT-/y 
animals and one-year old wild-type mice (n = 4). The mean distance to locate 
the platform on the last three days of training (t-test, p = 0.968) and the probe 
test revealed a similar learning and memory impairment in these two 
experimental groups (Two-Way RM ANOVA, p = 0.479; Figure 11). 
 
Figure 11. Premature cognitive decline in CrT null mice. (A) No difference was found in the mean 
swimming path on the last three days of training between P365 CrT+/y (n = 4) and P180 CrT-/y 
animals (n = 7; t-test, p = 0.968). (B) In the probe test, the percentage of time spent in the different 
two quadrants was totally comparable in P180 CrT-/y mice and six-month older CrT+/y animals 
(Two-Way RM ANOVA, p = 0.479). Error bars: SEM. 
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EMOTIONAL PHENOTYPE IS NOT ALTERED IN CRT MUTANT 
ANIMALS 
To rule out the possibility that significant differences in cognitive 
capacities reflect changes in the ability to cope with stress in challenging task 
conditions, we analyzed the general activity and anxiety-related behavior of 
CrT-/y and CrT+/y mice in the open field arena at the different ages used for 
cognitive assessment. We found that the time spent by CrT-/y mutant mice (n 
= 12 for P40 and P100, n = 11 for P180) in both the central and peripheral 
portion of the apparatus was not different from that recorded for WT animals 
(n = 13 for P40 and P100, n = 11 for P180) at any of the time point tested 
(Two-Way ANOVA, post hoc Holm-Sidak method, p = 0.725 at P40, p = 
0.508 at P100 and p = 0.348 at P180), indicating that the vulnerability to 
stress and anxiety responses are not sensitive to CrT deletion and excluding 
the hypothesis that the progression of cognitive deficit might be related to 
altered emotionality (Figure 12). 
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Figure 12. Normal behavior of CrT mutant mice in the open field arena. Left, CrT+/y and CrT-/y mice 
spent a comparable amount of time in the center and in the peripheral region of the open field arena. 
A Two-Way ANOVA analysis shows no significant effect of genotype at P40 (CrT+/y n = 13, CrT–/y 
n = 12; p = 0.725; panel A), P100 (CrT+/y, n = 13, CrT-/y, n = 12; p = 0.508; panel B) and P180 
(CrT+/y, n = 11, CrT-/y, n = 11; panel C; p = 0.348). Right, total distance moved did not differ 
between CrT mutants and wild-type animals at all ages tested (t-test, p = 0.363, p = 0.452 and p = 
0.101, respectively). Representative examples of movement path during the open field session for a 
CrT+/y and a CrT-/y mouse are also reported. Error bars: SEM. 
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CRT-/Y MICE EXHIBIT INCREASED REPETITIVE AND STEREOTYPED 
BEHAVIOR 
Since the clinical picture of CCDS1 patients includes multiple traits 
linked to autism spectrum disorders (ASDs), we also examined social 
behavior in CrT null mice. Although we used two different social interaction 
paradigms, we detected no abnormalities in CrT-/y mice at P180. In the social 
preference test, indeed, both CrT-/y (n = 8) and CrT+/y (n = 6) animals spent 
significantly more time exploring the wire cup housing the conspecific 
subject (Mann–Whitney Rank Sum test, p = 0.662; Figure 13A). Similarly, 
the index measured in the social novelty task did not differ between mutant 
and WT mice (t-test, p = 0.784; Figure 13A). 
The second core ASD symptom domain includes repetitive and 
stereotyped movements, routines and rituals (Etherton et al., 2009) and 
several mouse lines with ASD-associated mutations exhibit enhanced 
learning on the accelerating rotarod, a task that requires formation and 
consolidation of a repetitive motor routine (Rothwell et al., 2014). Thus, we 
tested rotarod abilities of CrT-/y (n = 12 for P40, n = 11 for P100 and n = 9 
for P180) and CrT+/y (n = 13 for P40 and P100, n = 11 for P180) animals, 
with the speed of rotation accelerating from 4 to 40 rpm over 600 s. The 
performance of CrT-/y mutant mice diverged from that of wild-type mice, 
with a significant increase of fall latency from the drum at all ages tested 
(Two-Way ANOVA, effect of genotype p < 0.001, post hoc Holm-Sidak 
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method, p < 0.01 at P40 and P100, p < 0.05 at P180; Figure 13B). We next 
examined self-grooming, another stereotyped behavior in mice (Fuccillo, 
2016). While no difference was present at P40 (CrT-/y, n = 9; CrT+/y, n = 7; 
Two-Way ANOVA on rank transformed data, post hoc Holm-Sidak method, 
p = 0.912) CrT null mice spent about threefold as much time grooming 
themselves as littermate WT mice at P180 (CrT-/y, n = 7; CrT+/y, n = 11; p < 
0.01; Figure 13C). 
CRT DELETION LEADS TO A WIDESPREAD CR REDUCTION IN YOUNG 
AND ADULT MICE 
To understand whether the progression of cognitive deficits in CrT-/y 
mice was due to a gradual reduction of brain Cr content, we measured Cr 
levels in various tissues in 1-month- and 6-month-old animals using GC/MS. 
At both ages, we observed a significant reduction of Cr in the brain (both 
cerebral cortex and hippocampus; Two-Way ANOVA on rank transformed 
data, post hoc Holm-Sidak method, p < 0.001), muscle (p < 0.001), heart (p < 
0.001) and kidney (p < 0.05) of CrT-/y mice with respect to WT littermates (n 
= 4/tissue for each group; Table 1). Importantly, no difference was detected 
in Cr levels measured in the different tissues between P30 and P180 CrT-/y 
mice, except for the muscle: a Three-Way ANOVA on rank transformed data 
analysis revealed a significant interaction (p < 0.001) 
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Figure 13. CrT mutation enhances repetitive and stereotyped behaviors. (A) Social interaction 
behaviors in CrT-/y mice. Histograms display discrimination indexes of CrT+/y (n = 6) and CrT-/y (n = 
8) mice during the social preference (session I) and the social novelty phase (session II). No 
difference was detected between the two groups (Mann–Whitney Rank Sum test, p = 0.662 for 
session I; t-test, p = 0.784 for session II). A schematic representation of the three-chamber test is 
also depicted. (B) Performance of littermate WT (n = 11) and CrT-/y mice (n = 9) on the accelerating 
rotarod. Inset shows an illustration of the rotarod apparatus. A Two-Way ANOVA showed a 
significant effect of genotype (p < 0.001). Post hoc Holm-Sidak test revealed that the fall latency of 
mutant animals was significantly different from that of wild-type mice at all ages tested (p < 0.01 at 
P40 and P100, p < 0.05 at P180). (C) Histograms display mean time spent self-grooming in CrT+/y 
and CrT-/y animals at P40 and P180. While no difference was detected at P40 (CrT+/y, n = 7; CrT-/y, n 
= 9; Two Way ANOVA on rank transformed data, post hoc Holm-Sidak method, p = 0.912), CrT 
null mice exhibit increased grooming behavior at P180 (CrT+/y, n = 11; CrT-/y, n = 7; p < 0.01). A 
schematic representation of self-grooming behavior is reported. * p < 0.05; # p < 0.01. Error bars: 
SEM. 
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Table 1. Cr levels (mean ± SEM) in CrT+/y and CrT-/y animals at P30 and P180 (n = 4 per tissue for 
both groups). Cr levels have been measured by GC/MS. A reduction of Cr content was evident in the 
brain, muscle, heart and kidney of mutant animals at both P30 and P180 (Two-Way ANOVA on 
rank transformed data, post hoc Holm-Sidak method). * p < 0.05; ** p < 0.01; *** p < 0.001 
 
 
Table 2. GAA levels (mean ± SEM) in CrT+/y and CrT-/y animals at P30 and P180 (n = 4 per tissue 
for both groups). At P30, a moderate increase of GAA content was evident in the brain and the 
muscle of mutant animals (Two-Way ANOVA on rank transformed data, post hoc Holm-Sidak 
method, p < 0.05), whereas GAA was decreased in the heart of CrT-/y animals (p < 0.05) and no 
difference was detected in the kidney tissue (p = 0.359). At P180, GAA levels were higher in the 
hippocampus and the muscle of mutant animals (Two-Way ANOVA on rank transformed data, post 
hoc Holm-Sidak method, p < 0.01), whereas no difference was detected in cortex, heart and kidney 
(p = 0.175, p = 0.320 and p = 0.920, respectively). ** p < 0.01; *** p < 0.001. 
 
between genotype and age only at level of muscular tissue with a significant 
reduction of Cr levels in P180 CrT-/y mice (post hoc Holm-Sidak method, p < 
0.001). A moderate change in GAA levels was observed in some tissues 
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(Table 2) suggesting that Cr deficiency leads to a compensatory attempt by 
upregulating Cr biosynthesis. Also, in this case GAA content measured in 
P180 animals reproduced the levels reported in younger tissues: a Three-Way 
ANOVA on rank transformed data revealed a significant interaction (p < 
0.001) between genotype and age only at level of muscular tissue, but this 
analysis only stressed a significant reduction of GAA levels in P180 CrT-/y 
(post hoc Holm-Sidak method, p < 0.05) and WT mice (p < 0.001). These 
results allow rejecting the hypothesis that higher GAA toxicity could underlie 
the observed age-related decline of cognitive functions in CrT-/y animals. 
MORPHOLOGICAL CHARACTERIZATION OF NEURAL CIRCUITS IN 
CRT-/Y MICE 
The morpho-functional organization of neural circuits in mice carrying 
CrT mutations has never been studied so far. Thus, we have investigated 
whether the accelerated decline of learning and memory functions in CrT-
deficient mice was accompanied by pathological changes in brain 
morphology. The cerebral cortex and the hippocampus were analyzed 
because they are strictly involved in the symptoms caused by CrT deficiency 
in mice and in humans. In the same animals subjected to behavioral 
characterization, we first evaluated the neuroanatomical architecture of 
prefrontal (PFC) and cingulate cortex (ACC) of P180 mice (n = 6 for both 
groups). Cortical thickness and neuronal cell density were estimated on 
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NeuN stained sections. No difference in the cortical thickness (t-test, p = 
0.785 for PFC and p = 0.880 for ACC; Figure 14) and neuronal density 
across cortical layers was observed in mutant animals (Two-Way ANOVA, p 
= 0.683 for PFC; Two-Way ANOVA on rank transformed data, p = 0.146 for 
ACC; Figure 14). 
 
Figure 14. Morphological characterization of cerebral cortex in CrT+/y and CrT-/y animals at P180 (n 
= 6 for both groups). (A) Left, cortical thickness of prefrontal cortex was comparable in the two 
groups of animals (t-test, p = 0.838). Right, no difference in neuronal cell density measured in 
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LOSS OF GABAERGIC SYNAPSES IN THE CEREBRAL CORTEX OF 
CRT-/Y MICE 
Since synaptic dysfunction is a feature commonly observed in normal 
aging and neurodegenerative disorders likely contributing to the pathology 
progression (Bano et al., 2011), we analyzed the synaptic punctate 
expression of vGlut1 and vGAT, respectively as synaptic markers of 
excitatory and inhibitory neurons, in the cerebral cortex of CrT-/y mice. While 
excitatory synapses were not affected by Cr deficiency (n = 6 for both 
groups; Mann–Whitney Rank Sum test, p = 0.792 for PFC; t-test, p = 0.340 
for ACC; Figure 15A), we detected a prominent loss of vGAT staining both 
in PFC and ACC, suggesting a specific contribution of GABAergic synaptic 
alterations to the neuropathological phenotype of CCDS1 (n = 9 for CrT-/y 
group, n = 8 CrT+/y group; t-test, p < 0.05 for both comparisons; Figure 15B). 
Importantly, the loss of vGAT-positive synapses overspread all the cortical 
layers.  
different layers (layer I/II/III, layer V, layer VI) and in the entire cortical thickness was detected 
between CrT+/y and CrT-/y mice (Two-Way ANOVA, post hoc Holm-Sidak method, p = 0.414, p = 
0.670, p = 0.526 and p = 0.837, respectively). (B) Left, cortical thickness of cingulate cortex was 
similar in the two experimental groups (t-test, p = 0.824). Neuronal cell density measured in 
different layers and in the entire cortical thickness was not different in the two groups (Two- Way 
ANOVA, post hoc Holm-Sidak method, p = 0.197, p = 0.454, p = 0.302 and p = 0.262, 
respectively). Representative immunostainings for NeuN from PFC and ACC of a CrT+/y and a 
CrT-/y mouse are also reported. Calibration bars: 100 μm. Error bars: SEM. 
68 
 
 
MICROGLIAL CELLS DYSREGULATION IN CR DEFICIENT BRAIN 
Since aberrant microglia activation is one of the main pathological 
hallmarks of brain aging (von Bernhardi, Eugenín-von Bernhardi and 
Eugenín, 2015; Matt and Johnson, 2016)  we have also evaluated Iba-1 
expression as a marker of possible morphological changes of microglia in the 
cerebral cortex (namely PFC) and the hippocampus (HP) of mutant mice.  
 
Figure 15. Synaptic neurotransmission in CrT+/y and CrT-/y animals at P180. (A) Left, representative 
immunostaining for vGlut1 from PFC and ACC of a CrT+/y and a CrT-/y mouse. Right, no difference 
in vGlut1 staining was detected between the two experimental groups (n = 6 for both groups) either 
in PFC (t-test, p = 0.792) or ACC (t-test, p = 0.340). (B) Left, representative immunostaining for 
vGAT from PFC and ACC of a CrT+/y and a CrT-/y mouse. The number of vGAT-positive puncta 
was significantly reduced both in the PFC and the ACC of mutant animals (n = 9) with respect to 
controls (n = 8; t-test, p < 0.05 for both comparisons). * p < 0.05. Calibration bars: 25 µm. Error 
bars: SEM. 
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During aging microglia cells undergo morphological changes towards 
a reactive phenotype with short, thickened and less ramified processes 
(Hefendehl et al., 2014). We found a strong increase of activated microglial 
cells in the brain of CrT null animals as compared to WT controls (n = 8 for 
both groups), with a parallel reduction of resting cells (Two-Way ANOVA, 
post hoc Holm-Sidak method, p < 0.01 for PFC and p < 0.05 for HP; Figure 
16A and B), indicating that the metabolic deficit caused by Cr deficiency 
leads to a dysfunction of brain-immune cells interactions and to a 
neuroinflammatory state that can contribute to the cognitive decline reported 
in CrT-/y mice. 
 
Figure 16. Pathological activation of microglial cells in CrT-/y animals (A) Left, representative 
immunostaining for Iba-1 from PFC of a CrT+/y and a CrT-/y mouse. Right, a significant increase of 
the percentage of activated microglial cells, with a parallel decrease of resting microglia, was 
detected in mutant mice with respect to wild-type animals (n = 8 for both groups; Two Way 
ANOVA, post hoc Holm-Sidak method, p < 0.01). (B) Left, representative immunostaining for Iba-
1 from the hippocampus (HP) of a CrT+/y and a CrT-/y mouse. Right, the percentage of activated 
microglia was increased in mutant mice, whereas the relative number of resting cells was reduced 
compared to controls (n = 8 for both groups; Two-Way ANOVA, post hoc Holm-Sidak method, p < 
0.05). * p < 0.05; ** p < 0.01. Calibration bar: 100 µm. Error bars: SEM. 
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REDUCED NEUROGENESIS AND ENHANCED LIPOFUSCIN 
ACCUMULATION IN THE HIPPOCAMPUS OF CRT-/Y MICE 
 It is well known that the rate of neurogenesis declines dramatically 
with age, and dysregulation of hippocampal neurogenesis is an important 
mechanism underlying the cognitive impairment associated with normal 
aging (Lee, Clemenson and Gage, 2012). In order to investigate whether CrT 
deficiency could affect hippocampal structure and impinge on the 
neurogenesis process, we examined neuronal proliferation through Ki67 
labelling in the dentate gyrus (DG) of wild type and CrT-/y mice (n = 6 for 
both groups). Stereological analysis first revealed that the hippocampal 
volume of mutant animals was markedly reduced with respect to that 
measured in control mice (t-test, p < 0.05; Figure 17A). The number of Ki67-
positive cell was significantly lower in the DG of CrT-/y animal at P180, with 
approximately 30% reduction (t-test, p < 0.01; Figure 17B and D). We also 
evaluated the number of immature neurons in hippocampal DG using the 
neuroblast marker doublecortin (DCX). DCX-positive cells were also 
significantly reduced in CrT null mice DG (t-test, p < 0.001; Figure 17C and 
E), demonstrating the impairment of adult hippocampal neurogenesis and 
suggesting another cellular substrate of the cognitive deficit present in the 
CrT null model. Another characteristic neuropathological finding in CrT 
mice was the massive accumulation of autofluorescent material (lipofuscin).  
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Figure 17. Neurogenesis impairment and enhanced lipofuscin accumulation in the hippocampus of 
CrT-/y animals at P180. (A) The hippocampal volume of CrT-/y mice was smaller compared to 
CrT+/y mice (n = 6 for both groups; t-test, p < 0.05). (B) Stereological counting revealed that the 
density of Ki67-positive cells was significantly reduced in the DG of CrT-/y mice, with 
approximately 30% reduction with respect to WT littermates (n = 6 for both groups; t-test, p < 
0.01). (C) A significant decrease of the DCX-positive immature neurons was detected in the 
hippocampus of adult CrT-/y mice compared to controls (n = 6 for both groups; t-test, p < 0.001). 
(D) Representative immunostaining for Ki-67, a nuclear protein required for cellular proliferation, 
from a CrT+/y and a CrT-/y mouse. (E) Representative immunostaining for DCX, a microtubule-
associated phosphoprotein expressed in early neuronal differentiation, from a CrT+/y and a CrT-/y 
mouse. (F) Representative images for lipofuscin autofluorescence from a CrT+/y and a CrT-/y mouse. 
(G) Six-month-old CrT-/y mice (n = 6) show extensive accumulation of autofluorescent material 
throughout the brain when compared to the wild-type control (n = 5). A significant increase of 
abnormal autofluorescent storage was mainly found in DG granular and polymorph layer of CrT -/y 
mice (t-test, p < 0.05). * p < 0.05; ** p < 0.01; § p < 0.001. Calibration bars: 50 µm. Error bars: 
SEM. 
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 Lipofuscin is a lipopigment consisting of aggregated products of 
lysosomal degradation, including oxidized and misfolded proteins, lipids, 
defective mitochondria and metal ions (Dunlop, Brunk and Rodgers, 2009). 
We observed a marked accumulation of autofluorescent lipofuscin 
throughout the brain, but the most prominent autofluorescent signal was seen 
in the DG hippocampal region. Lipofuscin deposition and accumulation 
within the hippocampal neurons is a marker of cellular senescence (Terman 
and Brunk, 2006; Assunção et al., 2011). Thus, we compared the area of 
lipofuscin granules in the brain cells of 6-month-old CrT-/y (n = 6) mice and 
their CrT+/y siblings (n = 5). The accumulation of lipofuscin was significantly 
exacerbated in the hippocampal DG of CrT-/y animals at P180 (t-test, p < 
0.05, Figure 17F and G). 
ELECTROPHYSIOLOGICAL CHARACTERIZATION 
We found no statistically significant difference in any of the electrical 
passive properties studied in neurons, between CrT-/y and CrT+/y. In 
particular, we did not find difference in membrane resistance (t-test: p = 0.27; 
CrT+/y n cells/mice = 42/15; CrT-/y: n cells/mice = 44/12; Figure 18A) and in 
membrane capacitance (t-test: p = 0.37; CrT+/y: n cells/mice = 43/15; CrT-/y n 
cells/mice = 43/12; Figure 18B). The membrane resting potential was only 
slightly but not significantly altered in CrT-/y mice compared to CrT+/y (t- 
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Figure 18. Passive properties of pyramidal neurons in L4 of V1 cortex. (A) No difference was 
observed in membrane resistance (in MΩ) between CrT-/y compared to control mice (t-test: p = 
0.27; CrT+/y n (cells/mice) = 42/15; CrT-/y: n (cells/mice) = 44/12). (B) No difference in membrane 
capacitance was found between CrT-/y and CrT+/y mice (t-test: p = 0.37; CrT+/y: n (cells/mice) = 
43/15; CrT-/y n (cells/mice) = 43/12). (C) Membrane resting potential was only slightly reduced in 
CrT-/y with respect to WT in a statistically non-significant manner (t-test: p = 0.14; CrT+/y: n 
(cells/mice) = 42/15; CrT‑/y: n (cells/mice) = 33/12). Mean ± SEM. 
 
test: p = 0.14; CrT+/y: n cells/mice = 42/15; CrT-/y: n cells/mice = 33/12; 
Figure 18C). We then recorded mIPSCs in voltage-clamp using patch-clamp 
technique, finding no difference in the distribution of the amplitude of 
mIPSCs between CrT-/y and CrT+/y (Mann-Whitney Rank Sum test: p = 
0.132; CrT+/y: n cells/mice = 35/15; CrT-/y: n cells/mice = 34/12, Figure 
19A), whereas we found a pronounced higher interevent interval in CrT-/y 
(Mann-Whitney Rank Sum test: p < 0.001; CrT+/y: median 132.4 ms; n 
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cells/mice = 35/15; CrT-/y: median: 215.9 ms; n cells/mice = 34/12, Figure 
19B), indicating a reduced frequency of mIPSCs in cortical pyramidal 
neurons. 
 
 
Figure 19. Properties of mIPSCs recorded in pyramidal neurons in L4 of V1 cortex. (A) The 
interevent interval was higher in CrT-/y mice compared to WT (x-axis is Log; Mann-Whitney Rank 
Sum test: p < 0.001; CrT+/y: median 132.4 ms; n (cells/mice) = 35/15; CrT-/y: median: 215.9 ms; n 
(cells/mice) = 34/12). (B) Absolute amplitude of mIPSCs was similar in CrT-/y mice and in CrT+/y 
(Mann-Whitney Rank Sum test: p = 0.132; CrT+/y: n (cells/mice) = 35/15; CrT-/y: n (cells/mice) = 
34/12). Median ± interquartile range. 
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NERVOUS SYSTEM-SPECIFIC CRT DELETION LEADS TO SIGNIFICANT 
CR REDUCTION IN THE CEREBRAL COMPARTMENT  
Since CrT-/y mice with ubiquitous deletion of the CrT gene showed a 
marked Cr depletion also in peripheral tissues, we analyzed the conditional 
nestin-KO in which CrT is deleted in post-mitotic neurons, glial cells and 
BBB endothelial cells by using the Nestin promoter to drive Cre-recombinase 
expression: nes-CrT mice (Tronche et al., 1999).  
In order to determine the validity of our approach for tissue-specific 
CrT gene deletion, we measured Cr levels in various tissues in 1-month- and 
6-month-old animals using GC/MS. At both ages, we observed a specific 
reduction of Cr in the cerebral cortex and the hippocampus of mutant mice 
(nes-CrT-/y) with respect to wild-type animals (CrT+/y) and Cre-recombinase 
expressing littermates (nes-CrT+/y), while no significant difference was 
detected between CrT+/y and nes-CrT+/y animals. Peripheral tissues including 
muscle, heart and kidney were not affected (n = 4/tissue for each group; 
Figure 20; Table 3Table 4). Only at P180, we detected a small difference of 
Cr  
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Table 3. Cr levels (mean ± SEM) in nes-CrT+/y, nes-CrT-/y and CrTfl/y animals at P180 (n = 4 per 
tissue for all groups). A reduction of Cr content was evident in the brain of mutant animals, while 
peripheral tissues were not affected (Two-Way ANOVA on rank transformed data, post hoc Holm-
Sidak method). *** p < 0.001 
 
 
Table 4. GAA levels (mean ± SEM) in nes-CrT+/y, nes-CrT-/y and CrTfl/y animals at P180 (n = 4 per 
tissue for all groups). An increase of GAA content was evident in the brain of mutant animals, 
while peripheral tissues were not affected (Two-Way ANOVA on rank transformed data, post hoc 
Holm-Sidak method). * p < 0.05; *** p < 0.001 
 
 
content between nes-CrT-/y and CrT+/y mice, which is likely due to the 
scattered expression of Nestin promoter in heart cells. At both ages, we 
observed that CrTfl/y animals not expressing Cre recombinase did not present 
a hypomorph phenotype, with normal levels of Cr in all tissues (Figure 20). 
Importantly, no difference was detected in Cr levels measured in the different 
tissues between P30 and P180. 
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Figure 20. Histograms show Cr levels in CrT+/y, nes-CrT+/y, nes-CrT-/y and CrTfl/y animals in brain 
and peripheral tissues at P30 and P180 (n = 4 per tissue for both groups). Cr levels have been 
measured by GC/MS. At both ages tested, a reduction of Cr content was evident in the cerebral 
cortex (Two-Way ANOVA on rank transformed data, post hoc Holm-Sidak method; P30: p < 0.05 
vs. CrT+/y, p < 0.001 vs. nes-CrT+/y, p < 0.01 vs. CrTfl/y; P180: p < 0.001 vs. CrT+/y, p < 0.01 vs. 
nes-CrT+/y, p < 0.001 vs. CrTfl/y) and the hippocampus of nes-CrT-/y mice (p < 0.001 for all 
comparisons at both ages). Muscle (Two-Way ANOVA on rank transformed data, post hoc Holm-
Sidak method; P30: p = 0.889 vs. CrT+/y, p = 0.965 vs. nes-CrT+/y, p = 0.880 vs. CrTfl/y; P180: p = 
0.985 vs. CrT+/y, p = 0.964 vs. nes-CrT+/y, p = 0.994 vs. CrTfl/y), heart (P30: p = 0.254 vs. CrT+/y, p 
= 0.624 vs. nes-CrT+/y, p = 0.969 vs. CrTfl/y; P180: p = 0.109 vs. nes-CrT+/y, p = 0.304 vs. CrTfl/y) 
and kidney (P30: p = 0.991 vs. CrT+/y, p = 0.971 vs. nes-CrT+/y, p = 0.937 vs. CrTfl/y; P180: p = 
0.213 vs. CrT+/y, p = 0.742 vs. nes-CrT+/y, p = 0.583 vs. CrTfl/y) of mutant animals were preserved 
from Cr depletion, with the exception of the heart at P180 showing slightly decreased Cr levels 
with respect to CrT+/y mice (p < 0.05). In addition, a Three-Way ANOVA on rank transformed data 
analysis revealed no difference for the age factor (p = 0.301).  * p < 0.05, # p < 0.01, § p < 0.001. 
Error bars: SEM. 
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REDUCED BODY WEIGHT GROWTH IN NES-CRT-/Y MICE 
Nes-CrT-/y animals (n = 6) showed a slightly reduced body weight 
compared to WT animals (n = 13) and nes-CrT+/y littermates (n = 9) at P100, 
P180 and P365, while no difference was present at P40 and P60 (Figure 21). 
Despite an age-dependent progressive increase of body mass in all 
experimental groups, the average decrease of body weight in nes-CrT-/y 
animals was about 10%. 
 
Figure 21. The weight of nes-CrT–/y mice (n = 6) was significantly reduced compared to CrT+/y (n 
= 13) and nes-CrT+/y animals (n = 9) at P100 (Two-Way ANOVA on rank transformed data, post 
hoc Holm-Sidak method, p < 0.05 vs. CrT+/y, p < 0.01 vs. nes-CrT+/y), P180 (p < 0.05 vs. CrT+/y, p 
< 0.001 vs. nes-CrT+/y) and P365 (p < 0.05 for both comparisons). No difference was detected 
among the three groups at P40 (Two-Way ANOVA on rank transformed data, post hoc Holm-Sidak 
method, p = 0.457 vs. CrT+/y, p = 0.373 vs. nes-CrT+/y) and P60 (p = 0.192 vs. CrT+/y, p = 0.069 vs. 
nes-CrT+/y), although the body weight of mutant animals is slightly lower even at these ages with 
respect to the other two groups. It is worth noting that age-dependent growth of body mass was not 
compromised in nes-CrT-/y animals showing a progressive increase of their weight (Two-Way 
ANOVA on rank transformed data, p < 0.001 effect of age, p < 0.05 for all age comparisons within 
CrT+/y, nes-CrT-/y and nes-CrT+/y groups). * p < 0.05, # p < 0.01, § p < 0.001. Error bars: SEM. 
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AGE-DEPENDENT DETERIORATION OF COGNITIVE FUNCTIONS IN 
BRAIN-SPECIFIC MUTANT MICE 
We then moved to assess the cognitive functioning of our model and 
to compare it with the result already seen in the ubiquitous model and in 
patients. With this aim and also to understand whether a progressive 
deterioration of learning and memory functions is present in nes-CrT-/y mice, 
we studied four different stages: I) during the brain development (P40 at the 
beginning of testing), II) in the adult age (P100 at the beginning of testing), 
III) in the middle age (P180 at the beginning of testing), and IV) in the early 
aging (P365 at the beginning of testing). Since mild secondary effects of Cre-
recombinase transgene insertion or Cre activity on selected endophenotypes 
have been previously suggested (Giusti et al., 2014) we also analyzed the 
behavior of nes-CrT+/y littermates at the same time points. We report a 
delayed onset of cognitive decline in nervous system-specific nes-CrT-/y mice 
with respect to whole-body CrT-/y mutants, followed by an age-dependent 
increase of cognitive frailty. No alterations of learning and memory, general 
exploratory activity, motor function and stereotypies were detected in the 
Nestin-cre mouse line. These results strengthen the concept that we already 
drawn from our ubiquitous model, that age is a key factor of mice carrying 
Cr deficiency. 
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Y MAZE IN NES-CRT-/Y  
We first analyzed the performance of nes-CrT-/y animals at P40 using 
the Y maze spontaneous alternation. Mutant nes-CrT-/y (n = 6), nes-CrT+/y 
littermates (n = 9) and control wild-type animals (CrT+/y, n = 13) equally 
explored the three arms of the maze with no bias towards a specific branch. 
Indeed, no effect of genotype was detected for the number of entries in the 
single arms of the maze (designated as A, B, C), despite an increased total 
number of entries by nes-CrT-/y mice (Figure 22A). At this age, the 
alternation rate was not different among CrT+/y, nes-CrT+/y and nes-CrT-/y and 
groups (Fig. 22A). In contrast, an impairment was detected at P100 and 
P180, with a significantly lower performance of nes-CrT-/y animals with 
respect to CrT+/y age-matched mice and nes-CrT+/y littermates (Figure 
22B,C). Also at these ages, the total number of entries by nes-CrT-/y mice is 
higher with respect to the two control groups, but no bias was present in the 
exploration of the three arms (Figure 22B,C). 
OBJECT RECOGNITION TEST (ORT) IN NES-CRT-/Y 
In the same animals, we assessed declarative memory abilities with the ORT, 
a test based on the natural tendency of rodents to spend more time exploring 
a novel object than a familiar one. No difference in short- (1h) and long-term 
(24h) recognition memory was detected at P40 in nes-CrT-/y mice (n = 6) 
with respect to CrT+/y (n = 10) and nes-CrT+/y animals (n = 8; Figure 23A).  
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Figure 22. At all ages tested, no effect of genotype was detected for the number of entries in the 
single arms of the maze (A, B, C; Two-Way ANOVA, post hoc Holm-Sidak method), while an 
higher total number of entries were scored for nes-CrT-/y mice  (P40: p < 0.001 vs. CrT+/y, p < 0.01 
vs. nes-CrT+/y; P100 and P180: p < 0.001 for both comparisons; A, B, C left). No difference in the 
Y maze performance was present among the three groups tested at P40 (CrT+/y, n = 12, nes-CrT+/y, 
n = 9, nes-CrT-/y, n = 6; One-Way ANOVA, p = 0.417, panel A right). In contrast, spontaneous 
alternation rate was significantly lower in nes-CrT-/y mice compared to that recorded for CrT+/y 
animals and nes-CrT+/y littermates at P100 (One-Way ANOVA, post hoc Holm-Sidak method, p < 
0.05 vs. CrT+/y, p < 0.01 vs. nes-CrT+/y; panel B right) and P180 (CrT+/y, n = 9, nes-CrT+/y, n = 9, 
nes-CrT-/y, n = 6; One-Way ANOVA, post hoc Holm-Sidak method, p < 0.05 for both comparisons; 
panel C right).  * p < 0.05, # p < 0.01. Error bars: SEM. 
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Figure 23. Left, diagrams describe total time of object exploration during the testing phase. (A, B, 
C) No difference was present among the different groups at all ages tested (One-Way ANOVA, 
P40: p = 0.372 for 1h and p = 0.686 for 24h; P100: p = 0.309 for 1h and p = 0.531 for 24h; P180: p 
= 0.097 for 1h and p = 0.526 for 24h). Right, histograms display object discrimination indexes of 
CrT+/y, nes-CrT+/y and nes-CrT-/y during the testing phase performed after a delay of 1 and 24h at 
different ages. (a) P40. The experimental groups (CrT+/y: n = 10, nes-CrT+/y: n = 8 and nes-CrT-/y: n 
= 6) can recognize the new object in the test both at 1h (One-Way ANOVA, p = 0.916) and at 24h 
(p < 0.183). (B) P100. While the three experimental groups can recall the memory of the familiar 
object in the test at 1h (One-Way ANOVA, p = 0.671), a significantly lower discrimination index 
was found in nes-CrT–/y mice (n = 6) compared to CrT+/y (n = 10) and nes-CrT+/y animals at 24h (n 
= 9; One-Way ANOVA, post hoc Holm-Sidak method p < 0.05 for both comparisons). (C) P180. A 
significant deficit of both short (One-Way ANOVA, post hoc Holm-Sidak method p < 0.05 for both 
comparisons) and long-term memory (One-Way ANOVA, post hoc Holm-Sidak method p < 0.05 
for both comparisons) was detected in mutant mice (n = 6) compared to controls (CrT+/y: n = 11, 
nes-CrT+/y: n = 9). * p < 0.05. Error bars: SEM. 
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The total time of object exploration during the test phase was also 
comparable among the three experimental groups. A memory deficit became 
apparent two months later, when the discrimination index at 24h was 
significantly lower in mutant mice, indicating a weakened capacity to recall a 
familiar object (P100, CrT+/y: n = 10, nes-CrT+/y: n = 9, nes-CrT-/y: n = 6; 
Figure 23B). This impairment eventually affected both short and long-term 
memories at P180. Indeed, at this age nes-CrT-/y mice showed a marked 
memory deficit both at 1- and 24-h interval between the sample and the test 
phase with respect to CrT+/y and nes-CrT+/y mice (CrT+/y n = 11, nes-CrT+/y n 
= 9, nes-CrT-/y n = 6; Fig. 23C). At both ages, total time of exploration was 
still comparable among groups (Figure 23B, C). 
MORRIS WATER MAZE (MWM) IN NES-CRT-/Y 
We further assessed memory abilities in the MWM task, a cognitive 
paradigm that allows testing spatial learning and memory. No difference was 
observed in the MWM performance of CrT+/y, nes-CrT+/y and nes-CrT-/y mice 
at P40 (CrT+/y: n = 10, nes-CrT+/y: n = 5, nes-CrT-/y: n = 5), P100 (CrT+/y: n = 
7, nes-CrT+/y: n = 5, nes-CrT-/y: n = 5) and P180 (CrT+/y: n = 9, nes-CrT+/y: n 
= 6, nes-CrT-/y: n = 5), with mutant animals being able to learn the task 
during the training phase and to remember the position of the platform in the 
probe trial as well as their age-matched controls (Figure 24A - C). At 1-year 
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Figure 24. Left, learning curves for CrT+/y (white), nes-CrT+/y mice (grey) and nes-CrT–/y (black)  at 
P40 (A; CrT+/y: n = 10, nes-CrT+/y: n = 5, nes-CrT-/y: n = 5), P100 (B; CrT+/y: n = 7, nes-CrT+/y: n = 
5, nes-CrT-/y: n = 5), P180 (C; CrT+/y: n = 9, nes-CrT+/y: n = 6, nes-CrT-/y: n = 5) and P365 (D; 
CrT+/y: n = 12, nes-CrT+/y: n = 14, nes-CrT-/y: n = 12). No significant difference was detected along 
the training phase at P40 (Two-Way RM ANOVA, effect of genotype p = 0.114, interaction 
genotype x day p = 0.999), P100 (effect of genotype p = 0.976, interaction genotype x day p = 
0.464) and P180 (Two-Way RM ANOVA on rank transformed data, effect of genotype p = 0.091, 
interaction genotype x day p = 0.748). In contrast, 1-year old nes-CrT-/y animals were poorer learners 
with respect to control groups, with a significant longer distance covered at day 5 and 6 of training 
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of age, however, nes-CrT-/y mice (n = 12) were significantly poorer learners 
with respect to age-matched CrT+/y (n = 12) and nes-CrT-/y animals (n = 14) 
so much so that the distance to locate the platform was different between the 
three groups at days 5 and 6 of training (Figure 24D, left). The probe test 
confirmed the presence of a spatial memory impairment in the conditional 
mutant mouse: animals not carrying the floxed allele, indeed, spent 
significantly longer time in the quadrant where the platform was located 
during the training days while mutant mice did not remember the location of 
the hidden platform and equally explored the four quadrants of the maze 
(Figure 24C, right). As expected, no effect of genotype was found on mean 
swimming speed recorded all along the training phase at the different ages 
tested (Figure 25), demonstrating that motor functions are largely preserved 
in the brain-specific CrT murine model. 
  
(Two-Way RM ANOVA, interaction genotype x day p < 0.05, post hoc Holm-Sidak method, p < 
0.05 for all comparisons at day 5, p < 0.01 vs. CrT+/y, p < 0.05 vs. nes-CrT+/y at day 6). Right, 
histograms showing the mean time percentage spent in the four quadrants during the probe trial. No 
significant difference among the three groups was present at P40 (A; Two-Way RM ANOVA, effect 
of genotype p = 0.173, interaction genotype x quadrant p = 0.985), P100 (B; effect of genotype p = 
0.111, interaction genotype x quadrant p = 0.856) and P180 (C; effect of genotype p = 0.133, 
interaction genotype x quadrant p = 0.985). At all ages, CrT+/y, nes-CrT+/y, nes-CrT–/y spent 
significantly more time in the NE* target quadrant than in the other ones (Two-Way RM ANOVA, 
post hoc Holm-Sidak method, p < 0.05 for all comparisons). At P365 (D), a Two-Way RM ANOVA 
followed by Holm-Sidak multiple comparison revealed that nes-CrT-/y did not show any preference 
for the target quadrant (p = 0.296 NE* vs. SO, p = 0.850 NE* vs SE, p = 0.060 NE* vs. NO), while 
CrT+/y and nes-CrT+/y spent significantly more time in the NE* target quadrant (p < 0.01 for all 
comparisons in CrT+/y, p < 0.001 for all comparisons in nes-CrT+/y). The percentage of time spent in 
the target quadrant was shorter in nes-CrT-/y mice than in the other two control groups (p < 0.05 for 
both comparisons). Representative examples of the swimming path during the probe session for a 
CrT+/y, a nes-CrT+/y and a nes-CrT-/y mouse are also depicted. * p < 0.05, # p < 0.01, § p < 0.001. 
Error bar: SEM. 
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Figure 25. Mean swimming speed measured all along the training phase of the Morris water maze 
for CrT+/y, nes- CrT+/y, and nes-CrT-/y animals at P40 (A; CrT+/y: n = 10, nes-CrT+/y: n = 5, nes-
CrT-/y: n = 5), P100 (B; CrT+/y: n = 7, nes-CrT+/y: n = 5, nes-CrT-/y: n = 5), P180 (C; CrT+/y: n = 9, 
nes-CrT+/y: n = 6, nes-CrT-/y: n = 5) and P365 (D; CrT+/y: n = 12, nes-CrT+/y: n = 14, nes-CrT-/y: n = 
12). At all ages tested, mutant nes-CrT-/y mice resulted to be good swimmers as well as control 
animals (One-Way ANOVA, p = 0.191 at P40, p = 0.336 at P100, p = 0.592 at P180, p = 0.177 at 
P365). Error bars: SEM. 
ANXIETY LEVELS AND MOTOR ACTIVITY ARE NOT ALTERED IN NES-
CRT-/Y MICE  
To exclude the possibility that differences in cognitive tasks reflect 
changes in anxiety levels and stress response, we evaluated general activity 
and anxiety-related behavior of CrT+/y mice, nes-CrT+/y and nes-CrT-/y in the 
open field arena following the same experimental schedule used for cognitive 
assessment (P40 and P100: CrT+/y n = 13, nes-CrT+/y n = 9, nes-CrT-/y n = 6; 
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P180: CrT+/y n = 11, nes-CrT+/y n = 8, nes-CrT-/y n = 6). Although all animals 
tended to remain in the peripheral region of the arena for a significantly 
longer time length, the time spent by nes-CrT-/y mutant mice in both the 
central and peripheral portion of the apparatus was not different from that 
recorded for CrT+/y and nes-CrT+/y animals at any of the time point tested 
(Figure 26). No difference was detected either in motion speed or total 
distance moved at P40 and P180, even if a decreased activity was observed in 
nes-CrT+/y at P100 (Figure 26). These data are in line with the lack of 
alterations in this test previously observed in the ubiquitous CrT mutant. 
To evaluate motor function in non-aversive environment, we also 
longitudinally investigated home-cage locomotor activity in this mouse 
model (P40 and P100: CrT+/y n = 13, nes-CrT+/y n = 9, nes-CrT-/y n = 6; 
P180: CrT+/y n = 11, nes-CrT+/y n = 9, nes-CrT-/y n = 6). We found that nes-
CrT-/y mice are significantly more active than the CrT+/y and the nes-CrT+/y 
group at P100. More specifically, nes-CrT-/y mice showed increased 
horizontal activity during the night period (Figure 27). In agreement with the 
data obtained with the open field test, no effect of genotype was observed at 
P40 and P180 Figure 27). Finally, we performed a direct measurement of 
muscle function using the conventional grip strength test in adult animals 
(P180; CrT+/y n = 13, nes-CrT+/y n = 11, nes-CrT-/y n = 7). Nes-CrT-/y mice 
displayed a forelimb strength totally comparable to wild-type and nes-CrT+/y 
animals (Figure 28). 
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Figure 26. Left, CrT+/y, nes-CrT+/y and nes-CrT-/y and CrT+/y mice spent a comparable amount of 
time in the center and in the peripheral region of the open field arena. A One-Way ANOVA on 
ranks analysis shows no significant effect of genotype at P40 (CrT+/y n = 13, nes-CrT+/y n = 9, nes-
CrT-/y n = 6; p = 0.384; panel A), P100 (CrT+/y n = 13, nes-CrT+/y n = 9, nes-CrT-/y n = 6; p = 0.162; 
panel B) and P180 (CrT+/y n = 11, nes-CrT+/y n = 8, nes-CrT-/y n = 6; p = 0.588; panel C). Middle 
and right, total distance moved and velocity did not differ between CrT conditional mutants and 
control animals at P40 and P180 (One-Way ANOVA, p = 0.159, p = 0.215, respectively), while 
nes-CrT+/y mice displayed a lower speed and, consequently, a shorter path covered in the arena at 
P100 (One-Way ANOVA on ranks, effect of genotype p < 0.01, post hoc Dunn’s method p < 0.05 
for both comparisons). * p < 0.05. Error bars: SEM. 
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Figure 27. Left, Time course of horizontal activity of CrT+/y (white), nes-CrT+/y (grey) and nes-
CrT-/y (black) animals during 24h at P40 (A), P100 (B) and P180 (C). Data are plotted as total 
number of beam crossings ± SEM in each time block of 60 min. Right, total horizontal distance 
travelled throughout 24h (total), and over the dark (night) or light phase (day). No significant 
difference was detected among the three experimental groups at P40 and P180 (Two-Way ANOVA 
on rank transformed data, p = 0.384 and p = 0.157, respectively), while nes-CrT-/y mice had a 
significant increase in motor activity at P100 in comparison to control groups during the night 
period (Two-Way ANOVA, post hoc Holm-Sidak method, p < 0.05 for both comparisons). * p < 
0.05. Error bars: SEM. 
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Figure 28. The performance of nes-CrT-/y mice (n = 7) in the grip strength displayed no significant 
difference with respect to CrT+/y (n = 13) and nes-CrT+/y (n = 11) animals (One-Way ANOVA, p = 
0.191). Error bars: SEM. 
ABSENCE OF PATHOLOGICAL REPETITIVE AND STEREOTYPED 
BEHAVIOR IN NES-CRT-/Y MICE  
CCDS1 patients can show traits linked to autism spectrum disorders. 
Moreover, as reported above, we found that ubiquitous CrT-/y mutant animals 
exhibit increased repetitive and stereotyped behavior. Thus, we examined the 
performance of CrT+/y mice (n = 13 for P40 and P100, n = 11 for P180 and 
P365), nes-CrT+/y (n = 9 for P40, P100 and P180, n = 11 for P365) and nes-
CrT-/y (n = 6 for P40, P100 and P180, n = 7 for P365) in the rotarod test and 
the amount of self-grooming at P180 (CrT+/y: n = 11, nes-CrT+/y: n = 11, nes-
CrT-/y: n = 7) and P365 (CrT+/y: n = 6, nes-CrT+/y: n = 10, nes-CrT-/y: n = 7; 
(Rothwell et al., 2014; Fuccillo, 2016). Nes-CrT-/y mutant mice did not differ 
from CrT+/y and nes-CrT+/y mice in the rotarod task, with a totally 
comparable fall latency from the drum at all ages tested (Figure 29A). The 
same was true for the self-grooming: indeed, no difference was present in the 
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time nes-CrT-/y, CrT+/y and nes-CrT+/y spent grooming themselves (Figure 
29B). These results suggest that the presence of autistic-like traits in the 
mouse model are related to the lack of Cr in tissues other than the CNS, that 
is: it seems to have a peripheral pathogenesis.  
 
Figure 29. (A) Longitudinal performance of CrT+/y mice (n = 13 for P40 and P100, n = 11 for P180 
and P365), nes-CrT+/y (n = 9 for P40, P100 and P180, n = 11 for P365) and nes-CrT-/y (n = 6 for 
P40, P100 and P180, n = 7 for P365) on the accelerating rotarod. A Two-Way ANOVA on rank 
transformed data showed no significant effect of genotype (p = 0.06) and the lack of a statistically 
significant interaction between genotype and age (p = 0.474). (B) Histograms display mean time 
spent self-grooming in CrT+/y, nes-CrT+/y and nes-CrT-/y at P180 (CrT+/y: n = 11, nes-CrT+/y: n = 11, 
nes-CrT-/y: n = 7) and P365 (CrT+/y: n = 6, nes-CrT+/y: n = 10, nes-CrT-/y: n = 7). No difference was 
detected in grooming behavior at both ages (Two-Way ANOVA on rank transformed data, effect of 
genotype p = 0.564, interaction genotype x age p = 0.131). Error bars: SEM. 
PROTEOMIC ANALYSIS OF MITOCHONDRIA IN UBIQUITOUS KO 
Comparative 2DE analysis. A comparative analysis between KO and 
WT 2DE proteomic maps was performed, at P12 and P30. Figure 30 
illustrates a representative 2DE image of mitochondrial protein extracts for 
WT and KO P30 samples, respectively. The quality of gels was assessed by 
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the software Same spot which includes the SpotCheck function. Overall an 
average of 1300 Spots was found within a nonlinear pH range from 3 to 10. 
Normalized spot volumes were analyzed by the ANOVA test to detect the 
proteins which were significantly (p < 0.05, q value < 0.05) differentially 
expressed between two classes. Fifty-five spots resulted differentially 
expressed in significant manner in CrT-/y with respect to CrT+/y at 30 days-
old, in particular 14 spots showed fold > 2. All these spots were increased in 
CrT-/y deficiency mice. Thirty-seven spots of interest were selected and cut 
from the gel and identify by nano-LC-ESI-MS/MS. A list of identified 
proteins, with molecular weight (MW), isoelectric point (pI), score, and 
coverage values of MS/MS is shown in Table 5 (at the end of this section). 
Only four spots resulted differentially expressed in significant manner in 
CrT-/y with respect to CrT+/y at 12 days-old (Table 6). 
 
Figure 30. Comparison between CrT-/y and WT proteomic gels. 
 
Pathway and Network Analysis. For the KO and WT comparison, 
proteins found differentially expressed were included in the Ingenuity 
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Pathways Analysis (IPA) analysis to identify molecular and cellular 
functions and to investigate whether these proteins work together in specific 
networks. Therefore, the software generated a main network (score 60) 
(Figure 31) with associated biofunctions “Free radical scavenging, small 
molecules biochemistry, neurological diseases” (Figure 32) and focused on 
canonical pathways which showed the differentially expressed molecules to 
fall into functional categories such as mitochondrial disfunction, glycolysis, 
sirtuin signaling, oxidative phosphorylation and Nrf2-mediated oxidative 
stress response (Figure 33). All the proteins found to be up- and down-
regulated may concur in an upstream regulator analysis to predict if 
transcription factors or genes could be activated or inactivated in agreement 
with the z-score value (z-score > ±2 and p < 0.05). A list of activated and 
inhibited factors is shown in Errore. L'origine riferimento non è stata 
trovata. and Figure 34 shows the interaction with the overexpressed proteins 
found in CrT-/y mice. In particular Rictor, fragile mental retardation protein 1 
(FMR1) and EGLN resulted inhibited whereas mTOR, NFE2L2, ESRRD and 
PPARGC1A resulted activated. Furthermore, a relationship between a top 
regulator, APP, and a molecular function, “metabolism of reactive oxygen 
species”, has been predicted in significant manner (Figure 35).  
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Figure 31. Main network generated by Ingenuity Pathways Analysis (IPA) software to show the 
relation between the identified proteins and to recognize cellular and molecular functions in which 
these proteins could be involved. 
 
 
Figure 32. Group of cellular functions or diseases to which the differentially expressed proteins are 
associated. 
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Figure 33. Main canonical pathways in which the differentially expressed proteins could be 
involved. 
 
 
Figure 34. Interaction of the factors identified, with the proteins differently regulated. 
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Figure 35. A main regulator, APP, interacts with many proteins identified by proteomic analysis, and 
a pathway emerges which converges towards the regulation of the metabolism of reactive oxygen 
species. 
 
Western Blot Validation of proteomic results. We selected 6 proteins 
to perform validation by immunoblot analysis. The results confirmed the 
significant different expression of six proteins in CrT-/y with respect to WT.  
For each tested protein the OD of specific immunoreactive band was 
determined and the resulting mean values were compared (CrT-/y vs WT). As 
shown in Figure 36, it is confirmed significant the increase of expression for 
all proteins analyzed. 
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Figure 36. Western Blot Validation of proteomic results. OD: optical density (normalized volume). 
KO: CrT-/y. Error bars: SEM. 
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Table 5. List of differentially expressed proteins at P30 identified by MS/MS spectrometry. ID: 
SwissProt accession number, MW (th): theorical molecular weight, pI (th): theorical isoelectric point 
(continuing to next pages).  
99 
 
 
 
100 
 
 
  
101 
 
 
 
  
Table 6. List of differentially expressed proteins at P12 identified by MS/MS spectrometry. ID: 
SwissProt accession number, MW (th): theorical molecular weight. 
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Table 7. List of the main putative upstream regulators and their interaction with the 
overexpressed proteins found in the CrT-/y mice. 
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DISCUSSION 
CCDS1 is known to cause brain Cr depletion and several neurological 
deficits, but nothing is known about the neurobiological bases of this disease. 
We performed the first thorough morphological, functional, behavioral and 
proteomic characterization of two CCDS1 mouse models, a ubiquitous KO 
model and a brain-specific KO. The latter is a novel conditional model in 
which exons from 5 to 7 are deleted (Baroncelli et al., 2014), compared with 
a previous model in which a deletion of exons 2 to 4 is used (Skelton et al., 
2011). However, in both models a dramatic reduction of brain Cr content is 
achieved, making them suitable for targeting CrT specifically in brain cells. 
Cr deficiency was apparent in both the cerebral cortex and 
hippocampus (which are two brain regions crucially involved in the patient 
cognitive defects) of both CrT-/y and nes-CrT-/y mice, and the reduction 
observed overlapped with the levels of Cr that are found in the brain of 
CCDS1 patients (van de Kamp et al. 2013). Similarly, Cr levels were 
completely preserved in the skeletal muscle of nes-CrT-/y as observed in 
CCDS1 subjects (deGrauw et al., 2003; Pyne-Geithman et al., 2004). In 
contrast, CrT-/y mice displayed a marked reduction of Cr in extraneural 
tissues, that does not match what is described in human patients, where the 
main organ involved is the brain and the other tissues seem relatively spared 
(Puusepp et al., 2010; Joncquel-Chevalier Curt et al., 2015).  
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The longitudinal analysis revealed a progressive cognitive decline not 
paralleled by either a decrease of Cr levels in the brain tissue or a rise of 
GAA (which is a toxic metabolite), strengthening the idea that the chronic 
deficit of Cr energy buffer is the main event triggering cellular and molecular 
compensatory mechanisms that bring about the progressive deterioration of 
brain function. The only tissue in which we were able to detect a significant 
reduction of Cr levels over time was the muscle, suggesting that 
compensatory upregulation of Cr in the muscle declines with age. This 
finding raises the possibility that a muscular phenotype could also occur in 
patients later in life.  
The phenotype associated with brain aging included progressive 
learning and memory deterioration, synaptic loss, microglial cell activation, 
neurogenesis impairment and lipofuscin deposition, and it already occurs in 
adult (i.e. not aged) animals. These significant differences in learning and 
memory performance of CrT-/y mice reflected changes in cognitive abilities 
per se: indeed, the open field test revealed that mutant mice display anxiety 
levels in the range of normal values, indicating that their capacity to cope 
with stressful conditions of behavioral tests is not altered.  
The cognitive decline was similar in both the ubiquitous and the 
conditional model, highlighting that a local CrT loss of function is sufficient 
to induce a dysregulation of Cr levels in the brain. However, the cognitive 
impairment observed in the nes-CrT-/y mice was delayed compared to 
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ubiquitous KO, and the conditional model lacks some traits usually linked to 
autism spectrum disorders, including repetitive and stereotyped movements, 
routines and rituals, all of which are present in CrT-/y. 
Nevertheless, these results clearly indicate that brain Cr depletion is a 
pivotal cause of the CCDS1 pathological phenotype, in particular with regard 
to the cognitive domain, but peripheral actors seem to play an important role. 
Future studies will allow elucidating the possible participation of peripheral 
metabolic alterations, blood biochemical milieu, immune abnormalities and 
intestinal microbiome in the etiology of CCDS1. 
Unexpectedly, our data about the nes-CrT-/y are not consistent with a 
very recent work showing that spatial learning and memory deficits are 
already present in young (P60 - 90) brain-specific knockout mice (Udobi et 
al., 2018). We surmise that this discrepancy might be due to a lack of 
motivating force in the animals used in the cited paper, as suggested by the 
altered performance in the cued version of the MWM, in which spatial 
memory is not required.  
The extent of the early aging that we observed is dramatically 
exemplified by the absence of difference in spatial learning performance 
when 6 months CrT-/y mice were compared to 12 months WT mice. We have 
considered the possibility that this accelerated decline in cognitive 
performance could be related to the documented neuroprotective (Matthews 
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et al., 1999; Sullivan et al., 2000; Bender et al., 2008; Puusepp et al., 2010) 
and antiapoptotic effects of Cr (O’Gorman et al., 1997). However, when we 
examined the neuronal density in the cerebral cortex, we did not detect any 
significant reduction in the number of NeuN-positive cells either in the PFC 
or in the ACC. In contrast, we found a marked impairment of hippocampal 
neurogenesis in the brain of mature CrT-/y mice. This was assessed by 
observing significantly reduced numbers of Ki67-positive proliferating cells 
along with DCX-positive immature neurons in the hippocampal DG region. 
These results are consistent with the notion that the creation of new neurons 
is an energetically expensive process (Kempermann, 2015) and that the 
hippocampus is particularly vulnerable to metabolic alterations (Bartsch and 
Wulff, 2015). Since adult hippocampal neurogenesis plays a vital role in 
maintaining normal cognitive processing (Christian, Song and Ming, 2014) 
an impairment of this process could conceivably compromise hippocampal 
function and represent a key substrate of the cognitive defects seen in CrT-/y 
mice. Accordingly, most studies indicate a correlation between a 
compromised neurogenic niche and impaired performance in hippocampus-
dependent cognitive tasks in aged mice (Lee, Clemenson and Gage, 2012). 
In many neurodevelopmental disorders, an imbalance between 
excitation and inhibition is described (Bories et al., 2013; McQuail, Frazier 
and Bizon, 2015). In particular, inhibition seems to play a pivotal role and the 
dysfunction of an important class of inhibitory interneurons, namely PV-
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expressing (PV+) cells, could be involved in autist-like disorders (Yizhar et 
al., 2011). We, therefore, performed electrophysiological studies using patch 
clamp recording of mIPSCs from cortical principal neurons. We found a 
reduced frequency of events, with a normal amplitude distribution. This 
could be associated with a reduction of release probability or with a 
decreased number of release sites. Morphological analysis revealed a 
reduction of presynaptic inhibitory puncta as indicated by the significant 
lower expression of the vesicular GABA transporter in two brain regions 
fundamentally involved in the processing of learning and memory tasks such 
as the PFC and the ACC. The whole picture, low mIPSCs frequency and less 
vGAT-expressing puncta, could be accounted for by a reduction of the 
number of inhibitory presynaptic release sites. These observations fit with the 
findings of a recent paper (Saunders et al., 2018) showing high expression of 
CrT in fast spiking PV+ inhibitory interneurons. These interneurons send 
axons to pyramidal neurons and to other PV+ cells as well, and because they 
can sustain high frequency firing, it is foreseeable that their energy 
requirement is very high. In turn this should require higher intracellular Cr 
levels and make them more vulnerable to Cr deficiency. The consequent 
dysfunction of inhibitory interneurons could explain the presence of epileptic 
phenotype in CCDS1 patients (Leuzzi et al., 2013) and some  
electroencephalogram (EEG) alterations (Schiaffino et al., 2005). 
Furthermore, the reduction of inhibition could represent another link to early 
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aging, since many studies describe a loss of inhibitory neurons in the aged 
brain (Shetty and Turner, 1998; Vela et al., 2003; Shi et al., 2004).  
Inflammation is increasingly being seen as a cardinal mechanism of 
aging (Franceschi et al., 2006), and we demonstrated that neuroinflammation 
plays a critical role in the progression of CrT disorder, enriching the 
framework of aging due to Cr deficiency. It is apparent that Cr depletion 
causes an aberrant activation of microglial cells in the brain of mature CrT-/y 
animals and activated microglia may release a number of cytokines and 
chemokines, which in turn activate many proinflammatory signal 
transduction pathways. It is known that coactivation of proinflammatory and 
cytotoxic products during neuroinflammation process is detrimental to 
neurons and may alter synaptic proteins (Rao et al., 2012). Recent evidence 
show that neuroinflammation also negatively affects hippocampal 
neurogenesis (Sierra et al., 2014; Ryan and Nolan, 2016). We could 
hypothesize that activated microglia-neuron crosstalk has detrimental effects 
on hippocampal neurogenesis and brain synaptic connectivity in CrT-/y 
animals. Thus, the dysregulation of microglial behavior appears to be a 
critical component of the negative progression of CrT deficiency pathology. 
A possible trigger of neuroinflammation is the increased concentration 
of damaged macromolecules and protein aggregates as a result of an increase 
in oxidative stress as well as a result of mitochondrial dysfunction leading to 
excessive generation of reactive oxygen species (ROS) and oxidative damage 
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to lipids, proteins and DNA. The Cr/PCr system is strongly implicated in the 
cellular bioenergetic function and several studies have revealed a correlation 
between Cr levels and intracellular ROS inasmuch Cr exhibits antioxidant 
activity either through direct interactions with oxidant species or through 
metabolic reactions conferring antioxidant protection (Lawler et al., 2002; 
Sestili et al., 2011). Accordingly, we found an enhanced accumulation of 
lipofuscin in the brain of CrT-/y mice that could be the result of increased 
oxidative damage (Höhn and Grune, 2013). The presence of lipofuscin can 
also influence important cellular processes, such as autophagy, by inhibiting 
the fusion between autophagosomes and lysosomes, thus further exacerbating 
the accumulation of degradation products and cognitive impairment 
(Brandenstein et al., 2016). In addition, patients with Cr deficiency 
syndromes have increased oxidative stress and ROS-induced apoptotic cell 
loss (Alcaide et al., 2011). 
All these results strongly point towards a picture in which the lack of Cr 
sets in motion the precocious activation of detrimental cellular and molecular 
mechanisms typical of brain aging leading to a progressive cognitive 
regression. Considering that the most important function of Cr is believed to 
be its energy-buffering property, and that mitochondria are the sites in which 
most of the cell energy is produced, the missing link between Cr lack and the 
subsequent cognitive decline could be represented by mitochondria 
themselves and their role in energy metabolism. To investigate deeper this 
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aspect, we performed a proteomic analysis of mitochondria enriched 
samples, which showed a marked alteration of the mitochondrial proteomic 
landscape in Cr deficient animals, with a total of 37 upregulated (identified) 
peptides in the brain of young (P30) CrT–/y mice. In contrast, pups carrying 
the same gene deletion at P12 did show a significant change of expression 
only in 4 proteins. Many of the differentially regulated peptides at P30 are 
enzymes and other proteins involved in the energy metabolism chain, 
including glucose metabolism, the tricarboxylic acid cycle, oxidative 
phosphorylation and fatty acid oxidation. Moreover, we observed an 
increased expression of multiple antioxidant enzymes.  
Therefore, a general pattern emerges of enhanced energy-generating 
pathways attempting to compensate for the power failure caused by Cr 
depletion. This forced metabolic phenotype is likely to originate an overload 
of potentially harmful by-products of cellular metabolism, which in turn 
activates the antioxidant defense system. Considering the central role of Cr in 
energy regulation, it is not surprising that brain Cr deficit, in the attempt to 
compensate for loss of efficiency in the cellular network of ATP distribution, 
resonates in abnormal cellular metabolism, eventually resulting in a shift of 
the critical balance between free radical generation and antioxidant 
protection. Accordingly, it has been shown that the skeletal muscle of AGAT 
knockout animals exhibits a conspicuous increase in inorganic 
phosphate/ATP ratio and overall mitochondrial content, paralleled by a 
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significant reduction of ATP levels (Nabuurs et al., 2013). Cellular 
metabolism and mitochondrial respiration increased in muscle fibers and 
brain of CrT-/y mice, with a higher number of mitochondria in CrT deficient 
cells (Perna et al., 2016). Moreover, pleomorphic and enlarged mitochondria, 
alterations of mitochondrial matrix and cristae appearance were observed at 
the electron microscope, in rats treated with an inhibitor of Cr uptake (Gori et 
al., 1988). Larger populations of motile mitochondria are present in cells 
with energy deficiency (Kuiper et al., 2008), potentially facilitating the 
recycling and elimination of damaged mitochondria. In agreement with this 
interpretation, we found an upregulation of several proteins pertaining to the 
lysosomal catabolic and the ubiquitin proteasome pathways. 
IPA enrichment analysis unveiled further cellular processes and 
components, which are impaired in CrT deficiency. The expression of 
cofilin-1 was 2-fold increased in Cr deficient brain compared to WT animals, 
suggesting that energy stress condition leads to the accumulation of this 
protein. Cytoplasmic cofilin rods have been demonstrated to disrupt dendritic 
transport, cause loss of dendritic spines and corrupt synaptic function in other 
neurological disorders including Alzheimer disease, bipolar disorders and 
autism (Chen and Wang, 2015; Woo et al., 2015; Shaw and Bamburg, 2017). 
Moreover, a possible link between cofilin, and mitochondrial dynamics and 
function has been proposed (Beck et al., 2012). Thus, neuronal dysregulation 
of cofilin might be involved in CCDS1 pathogenesis. A possible trigger of 
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cofilin polymerization is the increased concentration of damaged lipids, 
proteins and DNA as a result of oxidative stress (Bamburg and Bernstein, 
2016), a phenotype indeed observed in our KO model.  
The excessive generation of ROS and dysfunctional mitochondria might 
also be involved in the overexpression of the mitogen-activated protein 
kinase 1 (MAPK1/ERK2) signal transduction pathway (Zhu et al., 2002). 
Depending on the cellular context, MAPK cascade plays a pivotal role in 
diverse biological functions including cell growth, adhesion, survival, 
differentiation, synaptic plasticity and spine dynamics (Thomas and Huganir, 
2004; Ratto and Pizzorusso, 2006), but ERK pathway may bidirectionally 
affect brain function and plasticity. A growing number of recent studies 
connect ERK kinase to autism spectrum disorders and other syndromes 
characterized by intellectual disability (Kalkman, 2012), providing evidence 
that developmental abnormalities in neurogenesis and cortical 
cytoarchitecture can be associated with a paradoxical increase of ERK 
signaling (Pucilowska et al., 2015; Grissom et al., 2018). Although we do not 
know whether the overexpression of ERK1 corresponds to an actual 
hyperactivation, it is described in literature that ERK1 activation is 
associated with inhibition of ERK2, and the latter seems to modulate 
positively long-term recognition memory (Silingardi et al., 2011); in 
agreement with this picture, both our KO models, the ubiquitous and the 
conditional one, show strong impairment in recognition memory.  These data 
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raise the possibility that normalization of ERK activity, by treatment with 
ERK inhibitor peptides (Papale et al., 2017; Pucilowska et al., 2018), might 
rescue the CNS phenotype recorded in CrT-/y mice. 
Our data also suggest that neuroinflammation and aberrant activation of 
microglial cells are crucial actors in the progression of CCDS1 disorder. It is 
known that activated microglia can release proinflammatory cytokines, such 
as peptidyl-prolyl cis-trans isomerase A (PPIA), also known as Cyclophilin 
A (Nigro, Pompilio and Capogrossi, 2013), another protein that we found 
overexpressed in CrT-/y. Research in animal models and humans provided 
compelling evidence supporting the critical function of PPIA in acute and 
chronic inflammatory diseases (Hoffmann and Schiene-Fischer, 2014). 
Interestingly, PPIA expression increases with aging (Nigro, Pompilio and 
Capogrossi, 2013). 
Finally, upregulation of pyridoxal kinase (PLK) expression may be 
involved in alterations of network excitability recurring in Cr deficiency 
syndromes (Leuzzi et al., 2013). Excessive pyridoxal phosphate 
concentration induced by increased PLK, indeed, may result in altered 
GABA levels (Ebadi and Klangkalya, 1979; Gospe, Olin and Keen, 1994) 
and/or the modification of specific residues on the GABA-A receptor 
producing the degeneration of GABAergic neurotransmission (Ishioka et al., 
1995). In addition, patients with inborn errors of metabolism affecting 
vitamin B6 concentrations in the brain present early-onset epilepsy (Wang 
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and Kuo, 2007; di Salvo et al., 2017). Therefore, the modulation of PLK 
expression may regulate seizure susceptibility in CCDS1 patients. 
Despite the absence of a clear overlap in the neural proteomic milieu at 
P12 and P30, IPA analysis indicates that antioxidative defense is 
precociously reinforced in the brain of CrT-/y mice, suggesting early 
compensatory changes to preserve the balance between ROS production and 
their detoxifying enzymes. It is worth noting that we did not find a Cr-
concentration dose-dependency for molecular changes detected in the 
proteomic analysis, with the progressive alteration of protein expression not 
being paralleled by either a decrease of Cr levels or a rise of GAA toxicity in 
the brain tissue. Indeed, Cr and GAA levels were totally comparable in the 
cortex and the hippocampus of P30 CrT-/y mice with respect to P12 genotype-
matched animals. These results suggest that the prolonged and continued lack 
of Cr energy buffer might set in motion detrimental mitochondrial and 
molecular mechanisms leading to free radical adverse reactions that 
accumulate with age throughout the brain and cause the gradual shutdown of 
its function. This hypothesis fits our findings of progressive deterioration of 
cognitive functions accompanied by a massive lipofuscin deposition in brain 
cells.  
The changes in expression levels of the specific genes that we observed 
require that upstream modulators (e.g. transcription factors, co-activators, 
etc.) must be activated or repressed. Interestingly, our model predicts that the 
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activation of the amyloid precursor protein (APP) would account for the 
overexpression of a significant subset of proteins, and this whole network 
would converge mainly towards the metabolism of ROS. APP is well known 
for its role in neural development (Nicolas and Hassan, 2014) and in 
Alzheimer disease. These findings need to be validated with further studies, 
but the prediction of APP activation in a picture dominated by a process of 
early aging is compelling, and, moreover, many studies have found a relation 
between APP expression and severe autism (Ray et al., 2011; Lahiri et al., 
2013) 
Among other up-stream regulators, some others are particularly worth 
mentioning. TP53 is predicted to be activated. Its role in brain in 
development has been highlighted in many studies (Brynczka and Merrick, 
2008; Di Giovanni and Rathore, 2012), and according to a recent gene 
expression analysis based on large database, the gene coding for TP53 is 
linked to neurodegeneration and alterations in mitochondrial DNA and 
energy metabolism (Diaz-Beltran, Esteban and Wall, 2016). 
RICTOR is predicted to be inhibited and the inhibition of this protein has 
been associated to inflammatory tissue infiltration, enhanced production of 
ROS and regulation of proliferation (Xu et al., 2018), alterations that we 
described in our models.  
mTOR is predicted to be activated: this protein is involved in many vital 
cell functions like regulation of energy metabolism and proliferation and it 
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has been linked to autism, epilepsy and neurodegenerative disorders (Lipton 
and Sahin, 2014). 
FMR1, fragile X mental retardation 1 protein, is predicted inhibited. The 
deficiency of the protein leads to severe learning deficits and intellectual 
disability, characteristic of the fragile X syndrome, another well-known 
defect of neurodevelopment (Vanderklish and Edelman, 2002). Further 
analysis with Western blot will be required to confirm the alterations of all 
these proteins as predicted by our analysis. 
This is the first proteomic analysis of brain samples in a CTD mouse 
model exploring molecular mechanisms linking Cr deficit, energy 
metabolism alterations and brain dysfunction. Previously, Zervou et al., 2016 
used a high-throughput approach to examine Cr-dependent changes in the 
myocardial proteome (Zervou et al., 2016) and RNA sequencing of CrT 
deficient fibroblasts revealed a possible impairment of extracellular matrix 
and cytoskeleton, suggesting a role for Cr in structural regulation of cells 
(Nota et al., 2014). Despite the great relevance of investigating the effects of 
Slc6a8 mutations at the whole-body level, CrT deficiency is primarily 
characterized by Cr depletion in the brain and unraveling the molecular 
pathophysiology affecting the cerebral compartment in animal models of this 
disorder could be a goldmine for the discovery of novel biomarkers and 
druggable targets. In particular, we believe that antioxidant drugs, 
inflammation inhibitors, and peptides modulating cofilin activity and ERK 
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signaling might be valid therapeutic avenues for CTD cure. Given the 
complexity and high dynamic range of biological samples, however, future 
studies will be required to confirm that cognitive and neuropsychiatric 
symptoms of CCDS1 disorder are amenable to targeted drug therapy. We 
also bring to attention that our findings corroborate the hypothesis that 
multiple disorders of impaired cognition and autistic-like behavioral 
disturbances converge onto a few fundamental cellular processes, such as 
spine dynamics and the ERK/MAPK signaling cascade, affecting brain 
structural and functional plasticity. 
In contrast to what observed at P30, only few proteins are differentially 
expressed at P12. This observation, if confirmed, can have translational 
relevance allowing to identify the exact time window in which many of the 
changes in the normal cell transcription program happen and could 
theoretically permit, together with early diagnosis, treating patients with 
drugs able to reverse these transcriptional alterations. 
All the findings described in this work indicate that a massive 
impairment of cell metabolism follows the lack of Cr and that a long chain of 
events, only the first of which involving Cr directly, is started. Each of these 
steps can become, after adequate studies, a putative molecular target for 
therapeutic strategies. 
The current study presents many elements of novelty: I) identification 
of the earliest cognitive phenotype observed so far in CCDS1 mice; II) 
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discovering of early aging, inflammation and progressive neurodegeneration 
as fundamental aspects of this disorder; III) description of molecular 
pathways altered in samples enriched with mitochondria; IV) first insights 
into alterations of inhibitory circuits. 
IMPACT ON CCDS1 PATIENTS 
The present results have demonstrated that brain-specific and 
ubiquitous CrT mull mice undergo to an early onset of brain aging. One 
fundamental conclusion emerging from this work is that CCDS1 is a 
metabolic disorder associated with early brain aging and that age should be a 
key factor to deal with in the clinical evaluation of patients. It has been 
previously reported that, in patients, intellectual disability becomes more 
pronounced with age (van de Kamp, Mancini, and Salomons 2014), but 
longitudinal studies in human are totally lacking and little is known about the 
progression of the disease. 
In addition, our CrT mouse model allowed us to discover alterations of 
cellular and molecular mechanisms that play a pivotal role in the generation 
of the CCDS1 neurological phenotype. Mutant mice displayed alteration of 
GABAergic system, reduction of hippocampal neurogenesis, marked 
activation of microglia, altered oxidative metabolism and disruption of 
relevant molecular networks related to cell metabolism, mitochondrial 
function and ROS, leading to a general cognitive deterioration progressively 
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worsening with age. Moreover, the conditional KO showed that extraneural 
Cr loss might participate in the pathogenesis of the whole phenotype showed 
by CrT mutants. 
This knowledge opens the important possibility to design targeted 
drug intervention protocols aimed at overcoming brain alterations. If we 
could rescue brain alterations underlying CCDS1, indeed, both clinical and 
behavioral amelioration should be achieved. The use of non-invasive 
methods for behavioral assessment suitable for longitudinal analysis and the 
morphological characterization of brain alterations in CrT-/y and nes-CrT-/y 
mice set a firm background for translational studies using this model, 
providing normative data and protocols necessary to validate potential 
treatment strategies prior to launching costly clinical trials.  
Finally, our data also suggest that these mice models may be useful for 
exploring the mechanisms of age-related damage in the brain. The 
conditional mouse model lacks the early phenotype and the autistic-like traits 
of CCDS1 patients, highlighting that it does not represent a comprehensive 
tool for preclinical evaluation of potential CCDS1 treatments. However, we 
showed that extraneural Cr loss might modulate the phenotype of CrT 
mutants, making the use of nervous system specific models like nes-CrT 
mice important tools to understand the pathogenetic mechanisms underlying 
neurological deficits induced by Cr deficiency. 
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A large number of neurodevelopmental and neurological disorders, 
including Down syndrome, Batten disease, progranulin deficiency, brain iron 
dysregulation, have been associated with early brain aging (Kopra et al., 
2004; Ahmed et al., 2010; Maccarinelli et al., 2015; Head et al., 2016). Thus, 
a better understanding of factors that accelerate age-related deterioration of 
cognitive performance is critical both for improving the likelihood for 
successful aging and for revealing pathological changes of translational 
value.  
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CONCLUSIONS 
Our work identifies new important features of CrT defects. In 
particular: 
I) CCDS1 is a progressive neurodegenerative disorder in which, even if 
Cr concentration does not significantly change during the aging, a set 
of maladaptive compensatory mechanisms (many of which are still to 
be identified) leads to a progressive damage of brain functions. 
II) Cell energy metabolism and mitochondria seem strongly involved in 
the pathogenesis of CCDS1 and they could represent useful potential 
targets for therapeutic interventions. 
III) Inflammation seems to play an important part in this progressive 
damage, and this observation can pave the way to treatment strategies, 
given the number of drugs already available to modulate the 
immune/inflammation response. 
IV) Neural circuits disruption involving inhibitory systems could give a 
huge contribute to many of the clinical aspects observed in patients, as 
epilepsy and cognitive impairment, since the excitatory/inhibitory 
balance is fundamental for the normal function of neural circuits. 
V) Factors outside the CNS are important in the pathogenesis of at least 
some aspects of the disorder, since the conditional KO model show 
difference in the timing of onset of some cognitive defects and in the 
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presence of stereotypies. This observation is in part foreseeable, 
because of the great importance that the “body” has to the 
development of the brain, but it also carries interesting questions about 
how and how far periphery contributes to the normal 
neurodevelopment and, therefore, to the pathogenesis of CCDS1. 
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ABBREVIATIONS 
ACC: anterior cingulate cortex. 
aCSF: artificial cerebro-spinal fluid. 
AGAT: L-arginine:glycine amidinotransferase. 
ADP: adenosine diphosphate. 
Arg: arginine. 
ASD: autism spectrum disorder. 
ATP: adenosine 5’-triphosphate. 
BBB: blood brain barrier 
CaMKII: Ca2+/calmodulin-dependent protein kinase II. 
CCDS1: cerebral creatine deficiency syndrome type 1. 
CK: creatine kinase. 
CNS: central nervous system. 
Cr: creatine. 
CrT: creatine transporter. 
CSF: cerebro-spinal fluid. 
CTD: creatine transporter deficiency.  
CycloCr: cyclocreatine. 
DG: dentate gyrus. 
DNA: deoxyribonucleic acid. 
GAA: guanidinoacetic acid. 
GAMT: guanidinoacetate methyltransferase. 
GCL: granule cell layer. 
GC/MS: gas chromatography/mass spectrometry. 
Gly: glycine. 
HP: hippocampus 
1H-MRS: proton magnetic-resonance spectroscopy. 
KO: knock-out. 
MIP: maximum intensity projection. 
mIPSC: miniature inhibitory post-synaptic potential. 
MWM: Morris water maze. 
ORT: object recognition test. 
PBS: phosphate buffered saline. 
PCr: phosphocreatine. 
PCR: polymerase chain reaction. 
PFC: prefrontal cortex. 
Pn: post-natal day n. 
PV: parvalbumin. 
ROS: reactive oxygen species. 
RT: room temperature. 
SEM: standard error of mean. 
WT: wild-type.  
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- A mouse model for creatine transporter deficiency reveals early onset 
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